<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">61235</article-id><article-id pub-id-type="doi">10.7554/eLife.61235</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title><italic>TINF2</italic> is a haploinsufficient tumor suppressor that limits telomere length</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-200948"><name><surname>Schmutz</surname><given-names>Isabelle</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7193-3922</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200949"><name><surname>Mensenkamp</surname><given-names>Arjen R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3805-877X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200950"><name><surname>Takai</surname><given-names>Kaori K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200951"><name><surname>Haadsma</surname><given-names>Maaike</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200952"><name><surname>Spruijt</surname><given-names>Liesbeth</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-136170"><name><surname>de Voer</surname><given-names>Richarda M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-5976"><name><surname>Choo</surname><given-names>Seunga Sara</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-117932"><name><surname>Lorbeer</surname><given-names>Franziska K</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3152-6852</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200953"><name><surname>van Grinsven</surname><given-names>Emma J</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198560"><name><surname>Hockemeyer</surname><given-names>Dirk</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5598-5092</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-200972"><name><surname>Jongmans</surname><given-names>Marjolijn CJ</given-names></name><email>M.C.J.Jongmans-3@umcutrecht.nl</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">†</xref></contrib><contrib contrib-type="author" corresp="yes" id="author-2227"><name><surname>de Lange</surname><given-names>Titia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9267-367X</contrib-id><email>delange@mail.rockefeller.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Laboratory for Cell Biology and Genetics, Rockefeller University</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Human Genetics, Radboud University Medical Center</institution><addr-line><named-content content-type="city">Nijmegen</named-content></addr-line><country>Netherlands</country></aff><aff id="aff3"><label>3</label><institution>Department of Molecular and Cellular Biology, University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Chan Zuckerberg Biohub</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>White</surname><given-names>Richard M</given-names></name><role>Senior Editor</role><aff><institution>Memorial Sloan Kettering Cancer Center</institution><country>United States</country></aff></contrib><contrib contrib-type="editor"><name><surname>Wellinger</surname><given-names>Raymund J</given-names></name><role>Reviewing Editor</role><aff><institution>Fac Medecine/Université de Sherbrooke</institution><country>Canada</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p> Princess Máxima Center for Pediatric Oncology, Department of Genetics, University Medical Center Utrecht, Utrecht, Netherlands</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>01</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e61235</elocation-id><history><date date-type="received" iso-8601-date="2020-07-20"><day>20</day><month>07</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-11-11"><day>11</day><month>11</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Schmutz et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Schmutz et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-61235-v1.pdf"/><abstract><p>Telomere shortening is a presumed tumor suppressor pathway that imposes a proliferative barrier (the Hayflick limit) during tumorigenesis. This model predicts that excessively long somatic telomeres predispose to cancer. Here, we describe cancer-prone families with two unique <italic>TINF2</italic> mutations that truncate TIN2, a shelterin subunit that controls telomere length. Patient lymphocyte telomeres were unusually long. We show that the truncated TIN2 proteins do not localize to telomeres, suggesting that the mutations create loss-of-function alleles. Heterozygous knock-in of the mutations or deletion of one copy of <italic>TINF2</italic> resulted in excessive telomere elongation in clonal lines, indicating that <italic>TINF2</italic> is haploinsufficient for telomere length control. In contrast, telomere protection and genome stability were maintained in all heterozygous clones. The data establish that the <italic>TINF2</italic> truncations predispose to a tumor syndrome. We conclude that <italic>TINF2</italic> acts as a haploinsufficient tumor suppressor that limits telomere length to ensure a timely Hayflick limit.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cancer predisposition</kwd><kwd>TIN2</kwd><kwd>telomere length</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>NIH</institution></institution-wrap></funding-source><award-id>R01-CA196884</award-id><principal-award-recipient><name><surname>Hockemeyer</surname><given-names>Dirk</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id><institution>U.S. Department of Defense</institution></institution-wrap></funding-source><award-id>W81XWH-19-1-0586</award-id><principal-award-recipient><name><surname>Hockemeyer</surname><given-names>Dirk</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><award-id>133396-RSG-19-029-01-DMC</award-id><principal-award-recipient><name><surname>Hockemeyer</surname><given-names>Dirk</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R35CA210036</award-id><principal-award-recipient><name><surname>de Lange</surname><given-names>Titia</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005190</institution-id><institution>Melanoma Research Alliance</institution></institution-wrap></funding-source><award-id>577521</award-id><principal-award-recipient><name><surname>de Lange</surname><given-names>Titia</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><award-id>Rose Zarucki Trust Research Professor</award-id><principal-award-recipient><name><surname>de Lange</surname><given-names>Titia</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001006</institution-id><institution>Breast Cancer Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>de Lange</surname><given-names>Titia</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Siebel Stem Cell Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Hockemeyer</surname><given-names>Dirk</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>Pew Charitable Trusts</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Hockemeyer</surname><given-names>Dirk</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001353</institution-id><institution>Alexander and Margaret Stewart Trust</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Hockemeyer</surname><given-names>Dirk</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Mutations in TIN2, a component of shelterin that keeps telomere length in check, lead to cancer-predisposition by disabling the telomere tumor suppressor pathway.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The idea that telomere attrition could repress the outgrowth of early stage cancer originates from the observation that telomeres shorten in normal human cells (<xref ref-type="bibr" rid="bib21">Harley et al., 1990</xref>; <xref ref-type="bibr" rid="bib23">Hastie et al., 1990</xref>; <xref ref-type="bibr" rid="bib11">de Lange et al., 1990</xref>; reviewed in <xref ref-type="bibr" rid="bib39">Maciejowski and de Lange, 2017</xref>). In agreement with this theory, telomere shortening leads to a proliferative barrier in vitro (the Hayflick limit <xref ref-type="bibr" rid="bib52">Shay and Wright, 2000</xref>) that can be overcome when telomerase is activated through expression of hTERT <xref ref-type="bibr" rid="bib3">Bodnar et al., 1998</xref>; telomerase activity is required to create tumorigenic derivatives from normal human cells <xref ref-type="bibr" rid="bib20">Hahn et al., 1999</xref>; and telomerase activation is a hallmark of human cancer (<xref ref-type="bibr" rid="bib51">Shay and Bacchetti, 1997</xref>). The discovery of hTERT promoter mutations in familial melanoma and other tumor types further solidified the view that telomere attrition is a barrier to tumorigenesis (<xref ref-type="bibr" rid="bib27">Horn et al., 2013</xref>; <xref ref-type="bibr" rid="bib29">Huang et al., 2013</xref>; reviewed in <xref ref-type="bibr" rid="bib38">Lorbeer and Hockemeyer, 2020</xref>).</p><p>For the telomere tumor suppression pathway to limit cancer incidence, telomeres need to shorten at the correct rate, which in most primary human cells is ~30–100 bp/end/cell division (<xref ref-type="bibr" rid="bib21">Harley et al., 1990</xref>; <xref ref-type="bibr" rid="bib30">Huffman et al., 2000</xref>). The number of cell divisions a transformed clone can execute before proliferation is curbed by one or more critically short telomeres depends on the initial telomere length. Most likely, it is the lengths of the shortest telomeres in a clone that determine its proliferative potential (<xref ref-type="bibr" rid="bib25">Hemann et al., 2001</xref>; <xref ref-type="bibr" rid="bib67">Zou et al., 2004</xref>). These considerations predict that excessive telomere length at birth will delay the Hayflick limit and create a permissive state for cancer development. Indeed, after removal of telomerase, a cancer cell line with very long telomeres remained tumorigenic until its telomere reserve was depleted (<xref ref-type="bibr" rid="bib54">Taboski et al., 2012</xref>). At birth, human telomeres have an average length that is specific to our species (<xref ref-type="bibr" rid="bib33">Kipling and Cooke, 1990</xref>; <xref ref-type="bibr" rid="bib17">Gomes et al., 2011</xref>). It is thought that this telomere reserve is sufficient to sustain the cell division needed for normal development and tissue homeostasis but becomes depleted during the over-proliferation associated with tumorigenesis. When and how human telomere length homeostasis is achieved has been difficult to discern.</p><p>In telomerase-positive tissue culture cells, telomere length homeostasis is mediated by shelterin (reviewed in <xref ref-type="bibr" rid="bib26">Hockemeyer and Collins, 2015</xref>). TIN2 is a central component in shelterin that binds to three other shelterin subunits. TIN2 interacts with both double-stranded telomeric DNA-binding proteins – TRF1 and TRF2 – and binds TPP1, which forms a heterodimer with the single-stranded telomeric DNA-binding protein POT1 (reviewed in <xref ref-type="bibr" rid="bib13">de Lange, 2018</xref>). TIN2 has been implicated as negative regulator of telomere length as have TRF1 and POT1 (<xref ref-type="bibr" rid="bib60">van Steensel and de Lange, 1997</xref>; <xref ref-type="bibr" rid="bib32">Kim et al., 1999</xref>; <xref ref-type="bibr" rid="bib37">Loayza and De Lange, 2003</xref>). The current model for telomere length homeostasis invokes a negative feedback loop, wherein telomerase is inhibited in cis by proteins (e.g. TRF1, TIN2, and POT1) that accumulate on the TTAGGG repeats synthesized by the enzyme.</p><p>It is well established that when telomeres are too short at birth, a devastating bone-marrow failure syndrome (dyskeratosis congenita [DC] and related syndromes) can arise. Missense mutations in a short stretch of amino acids of TIN2 (the DC patch) are responsible for ~25% of DC cases (<xref ref-type="bibr" rid="bib49">Savage et al., 2008</xref>; <xref ref-type="bibr" rid="bib61">Walne et al., 2008</xref>; reviewed in <xref ref-type="bibr" rid="bib50">Savage and Bertuch, 2010</xref>), whereas the majority of DC cases are due to mutations impinging on telomerase biogenesis and activity.</p><p>Recent data on cancer-associated mutations in <italic>POT1</italic> have provided a hint that long telomeres may predispose to cancer. Inherited <italic>POT1</italic> mutations in cancer-prone families are associated with excessively long telomeres in somatic cells (<xref ref-type="bibr" rid="bib47">Robles-Espinoza et al., 2014</xref>; <xref ref-type="bibr" rid="bib43">NCI DCEG Cancer Sequencing Working Group et al., 2014</xref>; reviewed in <xref ref-type="bibr" rid="bib18">Gong et al., 2020</xref>). However, the <italic>POT1</italic> mutations also lead to genome instability, which has been invoked as the main pathogenic determinant (<xref ref-type="bibr" rid="bib46">Ramsay et al., 2013</xref>; <xref ref-type="bibr" rid="bib45">Pinzaru et al., 2016</xref>; <xref ref-type="bibr" rid="bib7">Chen et al., 2017</xref>; <xref ref-type="bibr" rid="bib19">Gu et al., 2017</xref>). Therefore, the <italic>POT1</italic> mutations have not provided unambiguous evidence for the idea that long telomeres predispose to cancer.</p><p>Here, we describe heterozygous loss-of-function mutations in <italic>TINF2</italic> in cancer-prone families. These mutations do not compromise telomere protection but create excessively long telomeres in vitro and in vivo. We conclude that the affected individuals are cancer-prone because their overly long telomeres thwart the telomere tumor suppressor pathway.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Germline <italic>TINF2</italic> mutations in families with cancer</title><p>In a routine diagnostic setting, whole-exome sequencing was performed on lymphocyte DNA of patients who developed multiple malignancies and/or had a striking family history of cancer. Germline variants in exon 5 of <italic>TINF2</italic> (encoding TIN2) were discovered in four probands (<xref ref-type="fig" rid="fig1">Figure 1A–C</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Three probands shared c.604G &gt; C, whereas the fourth carried c.557del. The six individuals in this study developed 14 malignancies (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), including three papillary thyroid carcinomas, three breast carcinomas, and two melanomas (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). No loss of heterozygosity was detected in six tumors tested and second hits in <italic>TINF2</italic> were excluded in four of the six tumors analyzed by whole-exome sequencing (F3:III-1; Astrocytoma, F2:II-1; Melanoma and breast cancer, F1:II-4; colorectal cancer (CRC), see also <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Multiple somatic driver mutations were identified, all previously associated with the tumor type in which the mutation was identified, such as <italic>BRAF</italic> (c.1799T &gt; A, p.Val600Glu) in CRC and melanoma, and <italic>PIK3CA</italic> (c.1624G &gt; A, p.Glu542Lys) in breast cancer (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). The tumors did not reveal a shared somatic mutational spectrum (data not shown). Based on these families, we suggest that carriers of the reported <italic>TINF2</italic> variants might benefit from regular thyroid and dermatological surveillance as well as more general cancer surveillance.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Germline mutations in <italic>TINF2</italic> identified in individuals with multiple malignancies.</title><p>(<bold>A</bold>) <italic>TINF2</italic> mutations and clinical features of affected individuals in four different families. Telomere length percentile is based on Flow-FISH data (see below <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). (<bold>B, C</bold>) Pedigrees of one of the c.604G &gt; C families (<bold>B</bold>) and the c.557del family (<bold>C</bold>) listed in (<bold>A</bold>). Probands are highlighted by arrows. Filled symbols indicate patients with confirmed <italic>TINF2</italic> mutations and their clinical features are indicated. Symbols with vertical lines denote individuals who have developed cancer but have not been tested for <italic>TINF2</italic> mutations. +: <italic>TINF2</italic> mutation; -: wild type for <italic>TINF2</italic>; ?: not tested. See also <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61235-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Pedigrees of two c.604G &gt; C <italic>TINF2</italic> families.</title><p>Pedigrees of two families with heterozygous c.604G &gt; C mutations listed in <xref ref-type="fig" rid="fig1">Figure 1A</xref>. Probands are highlighted by arrows. Filled symbols indicate patients with confirmed <italic>TINF2</italic> mutations and clinical features are indicated. Symbols with vertical lines stand for individuals who have developed cancer but were not tested for the presence of the <italic>TINF2</italic> mutations.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61235-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Somatic mutations in the COSMIC cancer gene census identified in malignancies in <italic>TINF2</italic> mutation carriers.</title><p>Table showing the somatic mutations identified in the tumors of families with <italic>TINF2</italic> mutations.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61235-fig1-figsupp2-v1.tif"/></fig></fig-group><p>Both <italic>TINF2</italic> mutations generated truncated proteins (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The c.557del mutation creates a shift in the reading frame after serine 186 that ends in a stop codon 23 amino acids downstream (p.(Ser186fs); <xref ref-type="fig" rid="fig2">Figure 2D</xref>). The c.604G &gt; C change disrupts the splice donor site of exon 5 (<xref ref-type="fig" rid="fig2">Figure 2A,B</xref>). Transcript analysis showed that in addition to the wild-type full-length transcript (ENST00000399423.8) and a transcript lacking exons 4 and 5 (ENST00000626689.2), patient samples contain an alternative transcript (604G &gt; C II, <xref ref-type="fig" rid="fig2">Figure 2A,B</xref>). Transcript c.604G &gt; C II lacks exon 5 and contains 20 extra nucleotides from intron 4. It appears to arise from an alternative splice donor site in intron four with a good splice site consensus score (alt D4; <xref ref-type="fig" rid="fig2">Figure 2B,C</xref>). This transcript was also observed in heterozygous RPE1 cells carrying the c.604G &gt; C change (see below). In addition, the +/c.604G &gt; C RPE1 cells contained a second allele-specific transcript (c.604G &gt; C I, <xref ref-type="fig" rid="fig2">Figure 2B</xref>) generated through an alternative donor site in intron five that bears a good splice site consensus sequence (alt D5; <xref ref-type="fig" rid="fig2">Figure 2B,C</xref> and see <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> below). The use of alt D5 results in the addition of 17 nucleotides from intron 5 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). This transcript was most likely missed in the analysis of the patient samples due to its lower abundance and co-migration with the wild-type full-length transcript. The c.604G &gt; C I and c.604G &gt; C II transcripts both have a frameshift in the TIN2 ORF and are predicted to encode truncated proteins (p.(L170fs) and p.(E202fs)) (<xref ref-type="fig" rid="fig2">Figure 2D</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Molecular analysis of transcripts resulting from <italic>TINF2</italic> mutations.</title><p>(<bold>A</bold>) Transcript analysis in peripheral blood lymphocytes (with and without cycloheximide treatment, CHX) from patients with the c.604G &gt; C <italic>TINF2</italic> mutation (F1:III-3 and F1:II-4; see <xref ref-type="fig" rid="fig1">Figure 1A</xref>) and a control individual. RT-PCR products were analyzed by Sanger sequencing. Wild-type full-length TIN2 mRNA, an alternative splice form found in wild-type cells (alt. splice exons 3–6) and mutant allele transcripts (604G &gt; C I and 604G &gt; C II) are indicated. Transcript 604G &gt; C I was identified in heterozygous +/c.604G &gt; C and homozygous c.604G &gt; C RPE1 cells. (<bold>B</bold>) Schematic showing the splicing of exons 3–6 for full-length wild-type <italic>TINF2</italic>, the alternative splice variant (exons 3–6), and the aberrant splicing occurring in cells with c.604G &gt; C mutations. Alt D4 and alt D5 indicate alternative splice donor sites. (<bold>C</bold>) Comparison of the consensus score of alternative splice donor sites alt D4 and alt D5 to splice donors D4 and D5 (as calculated by Human Splicing Finder <ext-link ext-link-type="uri" xlink:href="http://www.umd.be">www.umd.be</ext-link>). (<bold>D</bold>) Schematic of wild-type TIN2, and the predicted truncations resulting from expression of c.557del p.(S186fs), c.604G &gt; C I p.(E202fs), and c.604G &gt; C II p.(L170fs). Exon boundaries and the regions involved in TIN2 interactions with TRF1, TRF2, and TPP1 and the DC patch are indicated. (<bold>E</bold>) Structure of the TIN2 TRFH domain (PDB ID: 5xyf; <xref ref-type="bibr" rid="bib28">Hu et al., 2017</xref>) with the amino acids at the truncation points highlighted. Peptides from TPP1 and TRF2 that interact with the TRFH domain are shown in the structure.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61235-fig2-v1.tif"/></fig></sec><sec id="s2-2"><title>Truncated versions of TIN2 do not bind TRF1 and do not localize to telomeres</title><p>The predicted truncated TIN2 proteins contain most of the N-terminal TRF homology (TRFH) domain of TIN2 where TRF2 and TPP1 bind and lack the TRF1-binding site and the short patch of amino acids mutated in dyskeratosis congenita (DC patch <xref ref-type="bibr" rid="bib49">Savage et al., 2008</xref>; <xref ref-type="bibr" rid="bib61">Walne et al., 2008</xref>; <xref ref-type="fig" rid="fig2">Figure 2D,E</xref>). To determine whether the truncated TIN2 proteins retain interactions with TIN2’s binding partners in shelterin, we generated expression constructs for the three predicted TIN2 truncations: L170fs and E202fs from c.604G &gt; C and S186fs from c.557del. Co-immunoprecipitation from 293T cells co-transfected with HA-tagged TIN2 versions and myc-tagged TRF1 showed that, as expected, the truncated forms of TIN2 had lost the ability to bind to TRF1 (<xref ref-type="fig" rid="fig3">Figure 3A,B</xref>). The interaction with TRF2 was preserved in the c.604G &gt; C derived E202fs truncation and was apparently enhanced in the c.557del-derived S186fs truncation (<xref ref-type="fig" rid="fig3">Figure 3A,B</xref>). In contrast, the c.604G &gt; C L170fs protein showed very little (or no) interaction with TRF2 (<xref ref-type="fig" rid="fig3">Figure 3A,B</xref>). The interaction with TPP1 was preserved in the E202fs version of TIN2 but not in the two other truncated forms (<xref ref-type="fig" rid="fig3">Figure 3A,B</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Truncated TIN2 versions show altered binding to shelterin subunits and diminished telomeric localization.</title><p>(<bold>A</bold>) Co-immunoprecipitation of myc-tagged TRF1 (left panel), TRF2 (middle panel) and TPP1 (right panel) from 293T cells co-transfected with HA-tagged wt TIN2, S186fs, L170fs, E202fs, or the empty vector. Inputs and HA-IPs were probed with HA antibody to detect TIN2 and with myc antibody to detect TRF1, TRF2, and TPP1. To achieve equal expression levels, the ratio of plasmids was: wt 1x, 186fs 2.5x, 202fs 2.5x, and 170fs 5x. This experiment was repeated three times with comparable results. (<bold>B</bold>) Summary of the interaction of wild type and mutant TIN2 alleles with TRF1, TRF2, or TPP1 as derived from multiple co-IP experiments as in (<bold>A</bold>). (<bold>C</bold>) Immunoblot showing expression of HA-tagged wild type and mutant TIN2 versions in 293T cells used for telomeric ChIP. (<bold>D</bold>) Dot blot assay for telomeric ChIP performed on the indicated 293T cells as shown in (<bold>C</bold>). (<bold>E</bold>) Quantification of telomeric DNA recovered with HA Ab (average relative % telomeric DNA recovered in three independent experiments, individual data points and means ± SD are shown). For the quantification, unpaired t-test was used to determine significance, p-values: ****p&lt;0.0001, ***p&lt;0.001, **p&lt;0.01, *p&lt;0.05. ns, not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61235-fig3-v1.tif"/></fig><p>Since the localization of TIN2 to telomeres is primarily determined by its ability to interact with TRF1 (<xref ref-type="bibr" rid="bib16">Frescas and de Lange, 2014</xref>), it is expected that the truncated proteins fail to efficiently accumulate at telomeres. In agreement, telomeric ChIP assays using the HA antibody on chromatin from 293T cells expressing the HA-tagged versions of TIN2 showed that the S186fs and L170fs proteins do not associate with telomeric DNA (<xref ref-type="fig" rid="fig3">Figure 3C–E</xref>). The E202fs protein may be slightly more proficient in telomeric association but the fraction of telomeric DNA recovered in the ChIP was not significantly increased compared to cells transfected with the empty vector. These data indicate that the truncated versions of TIN2 have lost the ability to function at telomeres.</p></sec><sec id="s2-3"><title>Telomeres are fully protected in cells heterozygous for c.604G &gt; C or c.557del</title><p>CRISPR/Cas9-mediated gene editing was used to knock in the c.557del and c.604G &gt; C mutations in RPE1-hTERT cells deficient for Rb and p53 (<xref ref-type="bibr" rid="bib64">Yang et al., 2017</xref>). The mutations were introduced using knock-in repair ssODN templates with the desired mutation, a mutated PAM, and a restriction enzyme recognition site used for screening of clonal cell lines (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). The CRISPR/Cas9 editing was designed to generate matched wild-type control clones with <italic>TINF2</italic> genes that were either unedited or edited with silent nucleotide changes (introduction of a restriction enzyme site and a mutated PAM). In addition, we targeted exon 1 of <italic>TINF2</italic> to generate heterozygous KO clones (TIN2+/KO or +/-; <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>) and accompanying control clones. For each genotype, several clones with the desired alterations were isolated (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>). The mutated clonal cell lines showed the same proliferation rate as the control clones (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5A</xref>). CRISPR/Cas9 editing of RPE1 cells also yielded a viable clone homozygous for the c.604G &gt; C mutation (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4B</xref>). Although this clone does not represent the genotype of the patients, it is useful as a positive control in telomere dysfunction assays. Transcript analysis of the heterozygous and homozygous c.604G &gt; C RPE1 clones confirmed expression of the c.604G &gt; C II mRNA identified in patient samples (see <xref ref-type="fig" rid="fig2">Figure 2A,B</xref>) and identified the c.604G &gt; C I transcript as an additional product from the mutated locus (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> and <xref ref-type="fig" rid="fig2">Figure 2B</xref>).</p><p>Clones heterozygous for the c.604G &gt; C or c.557del mutation and the TIN2+/- clones had slightly lower TIN2 protein levels relative to the controls (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>). Based on telomeric chromatin immunoprecipitation (ChIP) and immunofluorescence (IF) analysis, cells heterozygous for the mutations retained TIN2, TRF1, TPP1, and POT1 at their telomeres, although the data do not exclude a moderate reduction in the association of these proteins with telomeres (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5B–G</xref>). In contrast, the homozygous c.604G &gt; C clone showed a complete absence of TIN2 in immunoblots and the presence of TIN2, TRF1, TPP1, and POT1 at telomeres was strongly reduced (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref> and <xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5E–G</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Heterozygous <italic>TINF2</italic> mutations do not cause telomere damage or genome instability.</title><p>(<bold>A</bold>) Immunoblot for TIN2 and γtubulin in control cells and the indicated clones with targeted <italic>TINF2</italic> alleles. (<bold>B</bold>) Quantification of the immunoblot shown in A. Unpaired t-test was used to determine significance. Symbols: *p&lt;0.05; ns, not significant (0.16). (<bold>C</bold>) Representative images of TIF analysis in control and indicated <italic>TINF2</italic> mutant cells. IF for 53BP1 (red), telomeric FISH (green) and DNA (DAPI, blue). (<bold>D</bold>) Quantification of percentage of telomeres colocalizing with 53BP1 foci. Data from ≥50 nuclei per cell line, with three cell lines per genotype (with the exception of the single c.604G &gt; C homozyg clone). (<bold>E</bold>) Representative metaphase spreads of cells with mutated <italic>TINF2</italic> alleles. Sister telomere associations (&gt;), telomere fusions (*), and a marker chromosome found in all clones (marker) are indicated. Telomere FISH (red), centromere FISH (green) and DNA (DAPI, gray). (<bold>F</bold>) Quantification of telomere fusions ≥20 spreads per cell line, with three cell lines per genotype (except for the single 604G &gt; C homozyg clone). (<bold>G</bold>) Quantification of the % of telomeres found in sister associations. Data from ≥20 spreads per cell line; three cell lines per condition, except for the single 604G &gt; C homozyg clone. For the quantification in (<bold>B</bold>), (<bold>D</bold>), (<bold>F</bold>), and (<bold>G</bold>) means ± SD and individual data points are shown. One-way ANOVA with Tukey post-test was used to determine significance, p-values: ****p&lt;0.0001, ***p&lt;0.001, **p&lt;0.01, *p&lt;0.05. ns, not significant. See also <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref>–<xref ref-type="fig" rid="fig4s6">6</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61235-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Transcript analysis in 604G &gt; C/+ cells reveals presence of two alternative <italic>TINF2</italic> transcripts (604G &gt; C I, 604G &gt; C II).</title><p>Transcript analysis in control cells and cells with c.604G &gt; C <italic>TINF2</italic> mutations. Wild-type and alternative (604G &gt; C I, 604G &gt; C II, alt. splice exons 3–6) transcripts are indicated. Alt. splice exons 3–6 is present in controls and mutant cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61235-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Knock-in strategy for introduction of c.557del and c.604G &gt; C mutations into RPE1 cells.</title><p>(<bold>A</bold>) Schematic of the <italic>TINF2</italic> locus showing landmarks relevant to CRISPR/Cas9-mediated knock-in of <italic>TINF2</italic> mutations. The single guide RNA (sgRNA) target regions and the primers used for genotyping (blue arrows) are indicated. (<bold>B</bold>) Schematic showing the reference sequence (yellow), the PAM (green), sgRNA sequences, and mutant and control (with silent mutations) repair templates that were co-transfected with the sgRNA/Cas9 vector. The upper panel shows the repair template used to introduce c.557del mutations and the lower panel the template used for c.604G &gt; C. Repair templates were designed to introduce the respective mutations, mutate the PAM sequence (green) and introduce restriction sites for screening (pink and purple). (<bold>C</bold>) Schematic showing that the introduced PAM mutations and added restriction sites do not change the amino acid sequence.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61235-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Strategy to generate TIN2+/- RPE1 clones.</title><p>(<bold>A</bold>) Schematic of the <italic>TINF2</italic> locus showing landmarks relevant to CRISPR/Cas9-mediated targeting of exon1. The single guide RNA (sgRNA) target region and the primers used for genotyping (blue arrows) are indicated. (<bold>B</bold>) Sequence of <italic>TINF2</italic> exon 1 with the 5′ UTR (gray) and coding region (blue). The PAM (green) and sgRNA sequence (blue) is indicated.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61235-fig4-figsupp3-v1.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Sanger sequencing of CRISPR/Cas9-engineered clones with <italic>TINF2</italic> mutations.</title><p>(<bold>A–C</bold>) Reference sequence with sgRNA sequence and PAM and the edited sequences (highlighted) of the obtained cell lines for c.557del (<bold>A</bold>), c.604G &gt; C (<bold>B</bold>) and TIN2+/- cells (<bold>C</bold>) and control cell lines.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61235-fig4-figsupp4-v1.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 5.</label><caption><title>Characterization of cells with targeted <italic>TINF2</italic> alleles.</title><p>(<bold>A</bold>) Growth curves of RPE1 control cells and cells with heterozygous c.557del or c.604G &gt; C, homozygous c.604G &gt; C mutations, or TIN2+/- cells. (<bold>B</bold>) Telomeric ChIP to determine the specificity of Abs for TIN2, TPP1, and POT1 compared to pre-immune serum (pre-imm). Cell lines used are indicated above the rows. (<bold>C</bold>) Telomeric ChIP analysis with TIN2, TPP1, or POT Ab in control, c.557del mutant and TIN2+/- cells. All samples were processed in parallel. The input shown is the same for the TIN2, TPP1, and POT1. (<bold>D</bold>) Quantification of telomeric DNA recovered with the respective Abs (mean ± SD, % telomeric DNA recovered in three clones per genotype for TIN2 and TPP1, and two clones for POT1). (<bold>E</bold>) Telomeric ChIP analysis with TIN2, TPP1, TRF1, and POT1 Ab in control and heterozygous and homozygous c.604G &gt; C clones. (<bold>F</bold>) Quantification of telomeric DNA recovered with the indicated Abs as in (<bold>D</bold>) (mean ± SD, % telomeric DNA recovered in three independent clones for control and heterozygous c.604G &gt; C). (<bold>G</bold>) IF-FISH for TIN2, TRF1, or TRF2 (red) and telomeres (green) in control cells and cells with heterozygous and homozygous c.604G &gt; C mutations.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61235-fig4-figsupp5-v1.tif"/></fig><fig id="fig4s6" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 6.</label><caption><title>Representation of TIFs, telomere fusions, and sister associations in the individual cell lines.</title><p>(<bold>A</bold>) Quantification of telomeres containing 53BP1 (≥50 nuclei per cell line, with individual cell lines from <xref ref-type="fig" rid="fig4">Figure 4D</xref> shown). (<bold>B</bold>) Quantification of telomere fusions (≥20 spreads per cell line, with individual cell lines from <xref ref-type="fig" rid="fig4">Figure 4F</xref> shown). (<bold>C</bold>) Quantification of sister associations (≥20 spreads per cell line, with individual cell lines from <xref ref-type="fig" rid="fig4">Figure 4G</xref> shown).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61235-fig4-figsupp6-v1.tif"/></fig></fig-group><p>The extent to which the <italic>TINF2</italic> mutations affected telomere protection was monitored via the telomere dysfunction induced foci (TIF) assay (<xref ref-type="bibr" rid="bib55">Takai et al., 2003</xref>), which measures the accumulation of 53BP1 at telomeres. Clones with heterozygous c.557del or c.604G &gt; C mutations had the same TIF response as the control cells (<xref ref-type="fig" rid="fig4">Figure 4C,D</xref> and <xref ref-type="fig" rid="fig4s6">Figure 4—figure supplement 6A</xref>). Similarly, the TIF response was not increased in the TIN2+/- clones compared to wild-type controls. In contrast, the homozygous c.604G &gt; C clone showed obvious loss of telomere protection (<xref ref-type="fig" rid="fig4">Figure 4C,D</xref> and <xref ref-type="fig" rid="fig4s6">Figure 4—figure supplement 6A</xref>), likely due to the reduced telomeric association of POT1, which is required to prevent the activation of ATR signaling at human telomeres (<xref ref-type="bibr" rid="bib14">Denchi and de Lange, 2007</xref>). These results indicate that one functional <italic>TINF2</italic> gene is sufficient to sustain full telomere protection and that the truncated TIN2 proteins do not have a dominant negative effect on telomere protection.</p><p>Similarly, analysis of metaphase spreads showed that heterozygosity for the <italic>TINF2</italic> mutations or the exon 1 KO allele did not induce a significant level of telomere dysfunction. Although cells carrying the homozygous c.604G &gt; C mutation showed elevated levels of sister telomere associations and a low level of chromosome fusions, such aberrations were not significantly increased in the heterozygous clones relative to wild type (<xref ref-type="fig" rid="fig4">Figure 4E–G</xref>, <xref ref-type="fig" rid="fig4s6">Figure 4—figure supplement 6B,C</xref>). Thus, <italic>TINF2</italic> is not haploinsufficient for telomere protection and the <italic>TINF2</italic> mutations are unlikely to induce cancer-promoting genome rearrangements.</p></sec><sec id="s2-4"><title>Excessive telomere elongation associated with c.604G &gt; C and c.557del</title><p>Telomere length analysis in lymphocytes from three patients carrying the c.604G &gt; C or c.557del mutations revealed a median telomere length above the 99th percentile as measured by Flow-FISH (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Similarly, individuals with the <italic>TINF2</italic> p.W198fs mutation showed telomeres that were approximately twofold longer based on qPCR (<xref ref-type="bibr" rid="bib24">He et al., 2020</xref>). The presence of exceptionally long telomeres in the c.604G &gt; C individuals was verified by genomic blotting, showing that both primary and EBV-immortalized lymphocytes from two patients carried telomeres of ~13 kb (<xref ref-type="fig" rid="fig5">Figure 5A</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Heterozygous <italic>TINF2</italic> mutations induce telomere lengthening.</title><p>(<bold>A</bold>) Telomeric Southern blot of <italic>Mbo</italic>I/<italic>Alu</italic>I-digested genomic DNA from immortalized and primary patient cells (lymphocytes), normal lung fibroblasts (MRC5), and HeLa1.3 cells. Median telomere length (MTL) is indicated. (<bold>B</bold>) Telomeric Southern blot of <italic>Mbo</italic>I/<italic>Alu</italic>I-digested genomic DNA from control clones and clones with heterozygous c.604G &gt; C mutations at the indicated PDs. Telomere length changes are indicated and were calculated over 48 PDs. (<bold>C</bold>) Quantification of median telomere length changes for control cells and cells with heterozygous c.604G &gt; C mutations. Three cell lines per genotype were analyzed in two independent experiments (symbols denote the individual cell lines). (<bold>D</bold>) Telomeric Southern blot as in (<bold>B</bold>) for control clones and clones with heterozygous c.557del mutations. (<bold>E</bold>) Quantification of median telomere length changes for control cells and cells with heterozygous c.557del mutations as in (<bold>C</bold>). (<bold>F</bold>) Detection of telomeres in <italic>Mbo</italic>I/<italic>Alu</italic>I-digested genomic DNA from control clones and clones with heterozygous c.557del mutation probed under native conditions with a telomeric probe for the 3’ overhang. The change in MTL over 28 PDs is indicated. (<bold>G</bold>) Telomeric southern blot as in (<bold>B</bold>) for control cells and TIN2+/- cells. The indicated telomere length changes were calculated over 42 PDs. (<bold>H</bold>) Quantification of median telomere length changes for control cells and TIN2+/- cells as in C. (<bold>I</bold>) Telomeric southern blot of <italic>Mbo</italic>I/<italic>Alu</italic>I-digested genomic DNA from control and TIN2+/- hESCs. All clones were generated and propagated in parallel and telomere length was determined at 28 days after the CRISPR/Cas9 targeting. (<bold>J</bold>) Quantification of the median telomere length (as determined by blotting as in (<bold>I</bold>)) for control and heterozygous hESCs clones (control, n = 5; TIN2+/KO, n = 4). Bar graphs in (<bold>C</bold>), (<bold>E</bold>), (<bold>H</bold>), and (<bold>J</bold>) show means ± SDs. <italic>P</italic>-values are based on unpaired t-test. ****p&lt;0.0001, ***p&lt;0.001, **p&lt;0.01, *p&lt;0.05. ns, not significant. See also <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1</xref>–<xref ref-type="fig" rid="fig5s3">3</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61235-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Long telomeres in <italic>TINF2</italic> c.604G &gt; C and c.557del patients and hESC CRISPR/Cas9 editing.</title><p>(<bold>A</bold>) Median telomere length (MTL) in individuals with <italic>TINF2</italic> truncations as measured by Flow FISH. (<bold>B</bold>) Schematic of the <italic>TINF2</italic> locus showing landmarks relevant to CRISPR/Cas9 mediated targeting of the allele in hESCs. The single guide RNA (sgRNA) target regions and the primers used for genotyping (blue arrows) are indicated. (<bold>C</bold>) PCR genotyping of hESC clones showing the longer wild-type and shorter edited allele.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61235-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>No evidence for increased telomere recombination in c.604G &gt; C mutant and Tin2+/- cells.</title><p>Quantification of telomeric sister chromatid exchanges (T-SCE) in RPE1 control cells, cells with heterozygous c.604G &gt; C, or TIN2+/- cells (≥15 spreads per cell line, and two cell lines per condition, means ± SD and individual data points are shown). Unpaired t-test was was used to determine significance, ns, not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61235-fig5-figsupp2-v1.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Mutant and control RPE1 clones show similar telomerase activity.</title><p>(<bold>A–C</bold>) TRAP assay using extracts from the indicated c.604G &gt; C (<bold>A</bold>), control and c.557del (<bold>B</bold>), or TIN2+/- (<bold>C</bold>) cells together with the respective control cell lines. Serially diluted extracts (500, 100, 25 cells) were subjected to the TRAP assay. H, heat-treated extract from 500 cells; TSR8, positive control. Mutant and wild-type controls were harvested and analyzed in parallel and the TRAP products were analyzed on two gels (left and right half of each panel).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61235-fig5-figsupp3-v1.tif"/></fig></fig-group><p>Consistent with the unusually long telomeres in the patients, telomere elongation was observed in RPE1 clones heterozygous for c.557del or c.604G &gt; C (<xref ref-type="fig" rid="fig5">Figure 5B–F</xref>). For each genotype, three cell lines were tested over up to 3 months of propagation with the appropriate control cell lines cultured and analyzed in parallel. The change in telomere length with population doublings (PDs) was measured in two independent experiments for each clone. As expected, the initial telomere lengths show clonal variation as has been observed in other cell lines (<xref ref-type="bibr" rid="bib4">Bryan et al., 1998</xref>; <xref ref-type="bibr" rid="bib56">Takai et al., 2010</xref>). Comparison of the telomere elongation per PD between the control clones and the heterozygous clones showed that both the c.557del and the c.604G &gt; C mutation resulted in a greater extension of the telomeres (<xref ref-type="fig" rid="fig5">Figure 5B–F</xref>). This was the case when the total telomeric DNA was detected in standard genomic blots and the same result was obtained when telomere length was evaluated based on hybridization of a probe to the 3′ overhang in native gels (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Similarly, cells heterozygous for the exon one truncation showed greater rates of telomere elongation and this phenotype was observed in RPE1 cells as well as in human embryonic stem cells (hESCs) heterozygous for a deletion of exons 4–7 (<xref ref-type="fig" rid="fig5">Figure 5G–J</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B,C</xref>). All RPE1 clones showed approximately the same telomerase activity (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). The observed telomere elongation is likely due to telomerase-mediated elongation because there was no evidence for increased telomere recombination in the cell lines (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>), and the telomeres did not show the typical heterogeneous size of ALT telomeres (<xref ref-type="fig" rid="fig5">Figure 5</xref>). An effect of TIN2 on telomerase-mediated telomere elongation is consistent with prior data showing that a truncated TIN2 protein induced dramatic telomere elongation in cells expressing telomerase but had no effect in telomerase-negative cells (<xref ref-type="bibr" rid="bib32">Kim et al., 1999</xref>). These data indicate that the <italic>TINF2</italic> gene is haploinsufficient for telomere length control and explain the telomere elongation phenotype in the patients.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>These data reveal <italic>TINF2</italic> as a haploinsufficient tumor suppressor gene. Inactivation of one <italic>TINF2</italic> allele through truncation mutations results in inherited cancer predisposition with high penetrance and severity. The spectrum of cancers in the <italic>TINF2</italic> families studied here is broad, including breast cancer, colorectal cancer, thyroid cancer, and melanoma, and several patients had multiple independent malignancies. Similarly, a recent report identified a <italic>TINF2</italic> truncation mutation in a large family affected by thyroid cancer and melanoma (<xref ref-type="bibr" rid="bib24">He et al., 2020</xref>). It is remarkable that inherited mutations in <italic>TINF2</italic> can have two widely distinct outcomes. While the loss-of-function mutations described here cause cancer through aberrant telomere elongation, missense mutations in the DC patch of <italic>TINF2</italic> cause bone-marrow failure syndromes that are due to excessive telomere shortening. These disparate outcomes reflect the dual role of TIN2, which uses its DC patch to promote telomere maintenance by telomerase, while keeping telomere length in check through its interaction with TRF1 and TPP1/POT1. Our genetic data underscore that telomere length at birth needs to be carefully controlled within a narrow range to prevent premature stem cell depletion on one hand and cancer on the other.</p><sec id="s3-1"><title>Genetic evidence for the telomere tumor suppressor pathway</title><p>It has proven difficult to test the idea that telomere shortening represents a tumor suppressor pathway. Apart from modeling in the mouse (<xref ref-type="bibr" rid="bib2">Artandi and DePinho, 2000</xref>), evidence in favor of this decades-old concept is derived largely from indirect or in vitro observations (reviewed in <xref ref-type="bibr" rid="bib39">Maciejowski and de Lange, 2017</xref>). The discovery of hTERT promoter mutations in familial melanoma and sporadic cancers argued that telomerase activation is a critical step in tumor progression (<xref ref-type="bibr" rid="bib27">Horn et al., 2013</xref>; <xref ref-type="bibr" rid="bib29">Huang et al., 2013</xref>; reviewed in <xref ref-type="bibr" rid="bib38">Lorbeer and Hockemeyer, 2020</xref>). However, it did not definitively establish that telomerase is needed to subvert the telomere tumor suppression pathway. The requirement for telomerase activation during cancer progression could also be due to its presumed ability to heal broken chromosomes arising during periods of genome instability.</p><p>Cancer-predisposing mutations in the POT1 subunit of shelterin also did not inform on the telomere tumor suppressor pathway because they have two outcomes of potential relevance to cancer. On one hand, the altered <italic>POT1</italic> alleles result in very long germline telomeres in the probands, consistent with the idea that telomere shortening curbs tumorigenesis (<xref ref-type="bibr" rid="bib43">NCI DCEG Cancer Sequencing Working Group et al., 2014</xref>; <xref ref-type="bibr" rid="bib47">Robles-Espinoza et al., 2014</xref>). On the other hand, the mutations were reported to induce genome instability (<xref ref-type="bibr" rid="bib46">Ramsay et al., 2013</xref>; <xref ref-type="bibr" rid="bib45">Pinzaru et al., 2016</xref>; <xref ref-type="bibr" rid="bib7">Chen et al., 2017</xref>; <xref ref-type="bibr" rid="bib19">Gu et al., 2017</xref>). Indeed, most reports concluded that the cancer predisposition associated with these POT1 alleles is due to genomic rearrangements. However, these studies largely relied on overexpression of mutant versions of POT1 and did not examine cells with the heterozygous POT1 mutations found in the patients.</p><p>The cancer-causing <italic>TINF2</italic> mutations that create long germline telomeres without affecting telomere protection now remove the ambiguity. In the <italic>TINF2</italic> cases affected by inherited cancer predisposition, it is extremely unlikely that genome instability contributes to tumorigenesis since we have not detected loss of telomere protection or genome instability in heterozygous cell lines whose genotype mimic the patient status. The simplest interpretation is that the patient’s frequent malignancies are due to a failure in the telomere tumor suppressor pathway. By extension, we argue that there is no need to invoke genome instability as a cancer-promoting aspect of the <italic>POT1</italic> mutations in familial cancer. The data presented here argue that the telomere elongation phenotype associated with the <italic>POT1</italic> mutations is sufficient to explain the higher incidence of cancer in these families.</p><p>According to our findings, exceptionally long telomeres can lead to cancer predisposition. Our conclusion is consistent with prior GWAS studies suggesting an effect of telomere length on cancer predisposition (<xref ref-type="bibr" rid="bib48">Rode et al., 2016</xref>; <xref ref-type="bibr" rid="bib58">Telomeres Mendelian Randomization Collaboration et al., 2017</xref>; reviewed in <xref ref-type="bibr" rid="bib41">McNally et al., 2019</xref>). It is therefore pertinent to consider measuring telomere length in cancer-prone families lacking other genetic risk factors. Our findings also suggest that caution is warranted with regard to efforts to interfere with the telomere shortening program in healthy individuals (<xref ref-type="bibr" rid="bib22">Harley et al., 2011</xref>).</p></sec><sec id="s3-2"><title>Telomere length homeostasis in vitro and in vivo</title><p>The elongated telomeres associated with the inherited <italic>POT1</italic> and <italic>TINF2</italic> mutations now suggest that the telomere length homeostasis observed in cultured cells reflect aspects of telomere length control in the human germline. In vitro, TRF1, TIN2, and POT1 have been implicated as negative regulators of telomere length largely based on the telomere elongation phenotype of dominant negative alleles (<xref ref-type="bibr" rid="bib60">van Steensel and de Lange, 1997</xref>; <xref ref-type="bibr" rid="bib32">Kim et al., 1999</xref>; <xref ref-type="bibr" rid="bib37">Loayza and De Lange, 2003</xref>). The role of TPP1 (which links POT1 to TIN2) is more complex because it acts to limit telomere extension through POT1 but also recruits telomerase to telomeres (<xref ref-type="bibr" rid="bib42">Nandakumar et al., 2012</xref>; <xref ref-type="bibr" rid="bib66">Zhong et al., 2012</xref>). How the shelterin subunits control telomerase activity in cis has remained opaque (reviewed in <xref ref-type="bibr" rid="bib26">Hockemeyer and Collins, 2015</xref>). It is clear that the trimeric Ctc1, Stn1, Ten1 (CST) complex is required to control the length of human telomeres but how CST blocks telomerase is still unknown (<xref ref-type="bibr" rid="bib62">Wan et al., 2009</xref>; <xref ref-type="bibr" rid="bib6">Chen et al., 2012</xref>; <xref ref-type="bibr" rid="bib15">Feng et al., 2017</xref>; <xref ref-type="bibr" rid="bib57">Takai et al., 2016</xref>). The finding that cell culture systems reflect regulatory pathways observed in vivo should spur further in vitro experiments designed to illuminate how telomere length homeostasis is achieved. An important question to be addressed is why TIN2 is haploinsufficient for telomere length control and which other shelterin components show this phenotype. Shelterin components that are haploinsufficient for telomere length control but not for telomere protection are of particular interest since loss-of-function mutations in these genes could predispose to cancer.</p></sec><sec id="s3-3"><title>When does TIN2 act as a tumor suppressor?</title><p><italic>TINF2</italic> mutations lead to unusually long telomeres in the peripheral blood lymphocytes of the patients reported here. It is assumed that such long telomeres reflect the long telomeres present in the bone marrow stem cells since the number of divisions separating bone marrow stem cells from peripheral lymphocytes is too limited to allow the low level of telomerase in lymphocytes to extend the telomeres substantially. If this assumption is correct, the patients are likely born with unusually long telomeres in most of their stem cell compartments.</p><p>How could such long stem cell telomeres have originated? One possibility is that the <italic>TINF2</italic> mutations lead to extended telomeres in the parental germline that are then inherited by the affected child. We argue that this scenario does not account for several observations. First, if long telomeres inherited from one parent were the cause of the cancer predisposition, all children of an affected parent would be equally predisposed to cancer. Our data and the co-segregation of the <italic>TINF2</italic> p.W198fs variant with cancer in one large family (<xref ref-type="bibr" rid="bib24">He et al., 2020</xref>), argues that this is not the case. Second, genomic blots indicate a single class of very long telomeres in the peripheral blood lymphocytes of adults with the <italic>TINF2</italic> mutations. If these individuals had inherited long telomeres from one parent and short telomeres from the other without further changes in telomere length (except for the usual telomere attrition), the telomeres should reveal two size classes, one of which is in the normal range. Our genomic blots show that this is not the case. Finally, simple inheritance of long telomeres from one parent would not delay the onset of the Hayflick limit, which is determined by the shortest telomeres in a clone. The normal-sized telomeres from the unaffected parent should allow the Hayflick limit to protect against cancer regardless of the presence of longer telomeres from the affected parent.</p><p>These considerations lead us to propose that the <italic>TINF2</italic> mutations act by inappropriately elongating telomeres during early development. Importantly, such a process would elongate the normal sized telomeres inherited from the unaffected parent, preventing the timely onset of the Hayflick limit. Since telomerase is detectable in a number of embryonic tissues during the first and second trimester (<xref ref-type="bibr" rid="bib63">Wright et al., 1996</xref>), it is reasonable to assume that tens of cell divisions take place during which the enzyme can elongate telomeres unless it is restrained by the telomere length homeostasis pathway. We imagine that the <italic>TINF2</italic> mutations exert their cancer-promoting effects in the first weeks or months after fertilization, resulting not only in long telomeres in the germline but also in all other stem cell compartments that are relevant to cancer development later in life. According to this reasoning, <italic>TINF2</italic> would be a tumor suppressor gene with a very specific window of opportunity, exerting its effect early in development but not later.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">293T</td><td valign="top">ATCC</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/-</td><td valign="top"><xref ref-type="bibr" rid="bib64">Yang et al., 2017</xref></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- <break/>+/604G &gt; C.1 clone 1–3 m</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Heterozygous for<italic>TINF2</italic> c.604G &gt; C</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- <break/>+/604G &gt; C.2 clone 2–23 m</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Heterozygous for<italic>TINF2</italic> c.604G &gt; C</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- <break/>+/604G &gt; C.3 clone 1–21 m</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Heterozygous for<italic>TINF2</italic> c.604G &gt; C</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- ctrl4 <break/>clone 1–4 c</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Control cell line</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- ctrl5 <break/>clone 1–13 c</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Control cell line</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- ctrl6 <break/>clone 5–8 c</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Control cell line</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- <break/>+/557del.1 clone 1–9 m</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Heterozygous for<italic>TINF2</italic> c.557del</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- <break/>+/557del.2 clone 1–14 m</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Heterozygous for<italic>TINF2</italic> c.557del</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- <break/>+/557del.3 clone 2–17 m</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Heterozygous for<italic>TINF2</italic> c.557del</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- ctrl1 <break/>clone 2–7 c</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Control cell line</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- ctrl2 <break/>clone 2–8 c</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Control cell line</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- ctrl3 <break/>clone 1–2 c</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Control cell line</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- <break/>+/-.1 clone 1-1het</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Heterozygous for <italic>TINF2</italic></td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- <break/>+/-.2 clone 1-3het</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Heterozygous for <italic>TINF2</italic></td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- <break/>+/-.3 clone 2-4het</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Heterozygous for <italic>TINF2</italic></td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- <break/>+/+ ctrl7 clone 2–9 c</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Control cell line</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- <break/>+/+ ctrl8 clone 3–2 c</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Control cell line</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">hTERT-RPE1 p53-/- Rb-/- <break/>+/+ ctrl9 clone 1–4 c</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Control cell line</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">WIBR3 hESC</td><td valign="top"><xref ref-type="bibr" rid="bib35">Lengner et al., 2010</xref></td><td valign="top">NIH stem cell registry number: 0079</td><td valign="top">Wild-type</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">WIBR3 hESC 1B1</td><td valign="top">This paper</td><td valign="top"/><td valign="top">+/+ <italic>TINF2</italic> Control cell line</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">WIBR3 hESC 3B4</td><td valign="top">This paper</td><td valign="top"/><td valign="top">+/+ <italic>TINF2</italic> Control cell line</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">WIBR3 hESC 3C2</td><td valign="top">This paper</td><td valign="top"/><td valign="top">+/+ <italic>TINF2</italic> Control cell line</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">WIBR3 hESC 5B1</td><td valign="top">This paper</td><td valign="top"/><td valign="top">+/+ <italic>TINF2</italic> Control cell line</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">WIBR3 hESC 3B3</td><td valign="top">This paper</td><td valign="top"/><td valign="top">+/- <italic>TINF2</italic></td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">WIBR3 hESC 4B4</td><td valign="top">This paper</td><td valign="top"/><td valign="top">+/- <italic>TINF2</italic></td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">WIBR3 hESC 5A4</td><td valign="top">This paper</td><td valign="top"/><td valign="top">+/- <italic>TINF2</italic></td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">WIBR3 hESC 5B3</td><td valign="top">This paper</td><td valign="top"/><td valign="top">+/- <italic>TINF2</italic></td></tr><tr><td valign="top">Anti-hTIN2</td><td valign="top"/><td valign="top"><xref ref-type="bibr" rid="bib65">Ye and de Lange, 2004</xref></td><td valign="top">#864</td><td valign="top"/></tr><tr><td valign="top">Anti-γTubulin</td><td valign="top"/><td valign="top">Sigma</td><td valign="top">GTU88</td><td valign="top"/></tr><tr><td valign="top">Anti-Myc</td><td valign="top"/><td valign="top">Cell signaling</td><td valign="top">9B11</td><td valign="top"/></tr><tr><td valign="top">Anti-HA</td><td valign="top"/><td valign="top">Abcam</td><td valign="top">Ab9110</td><td valign="top"/></tr><tr><td valign="top">Anti-53BP1</td><td valign="top"/><td valign="top">Abcam</td><td valign="top">ab175933</td><td valign="top"/></tr><tr><td valign="top">Cy3-OO- (TTAGGG)<sub>3</sub></td><td valign="top"/><td valign="top">PNA bio</td><td valign="top"/><td valign="top">Telomere probe</td></tr><tr><td valign="top">FITC-OO-(CCCTAA)<sub>3</sub></td><td valign="top"/><td valign="top">PNA bio</td><td valign="top"/><td valign="top">Telomere probe</td></tr><tr><td valign="top">Alexa Fluor 647-OO-(TTAGGG)<sub>3</sub></td><td valign="top"/><td valign="top">PNA bio</td><td valign="top"/><td valign="top">Telomere probe</td></tr><tr><td valign="top">CENPB-AF488</td><td valign="top"/><td valign="top">PNA bio</td><td valign="top">F3004</td><td valign="top">Centromere probe</td></tr></tbody></table></table-wrap><p>No statistical methods were used to predetermine sample size. Key resources are listed in the key resource table.</p><sec id="s4-1"><title>Patient selection</title><p>As part of routine diagnostic procedure, whole exome sequencing and subsequent cancer predisposition panel analysis was performed on patients who developed multiple malignancies or had a striking family history of cancer. The four index patients reported in this study were sequenced between 2014 and 2019 and were part of a total cohort of 446 patients referred for this diagnostic procedure. Whole exome sequencing was performed with relevant clinical quality accreditations and consent procedures as approved by the IRB equivalent (Medisch Etische Toetsingscommissie) of the Radboud University Medical Center. All participants (four probands and two affected relatives) provided written informed consent for publication of their data.</p></sec><sec id="s4-2"><title>Whole exome sequencing</title><p>Genomic DNA was isolated from whole blood. The experimental workflow of all exomes was performed at BGI Europe (Beijing Genome Institute Europe, Copenhagen, Denmark). Exonic regions were enriched using the Agilent (Agilent Technologies, CA, USA) SureSelect V4 (<italic>n</italic> = 85) or V5 (<italic>n</italic> = 169) kit and sequenced using an Illumina Hiseq (Illumina, CA, USA) sequencer with 101 bp paired end reads to a median coverage of &gt;75 x. Sequenced reads were mapped to the hg19 reference genome using the mapping algorithm from BWA (<xref ref-type="bibr" rid="bib36">Li and Durbin, 2010</xref>) (version 0.5.9-r16) and called by the GATK unified genotyper (<xref ref-type="bibr" rid="bib40">McKenna et al., 2010</xref>) (version 3.2–2). All variants were annotated using an in-house pipeline for exome analysis containing variant and gene-specific information. This information includes the variant population frequencies from &gt;5000 in-house whole exome analyses performed (<xref ref-type="bibr" rid="bib34">Lelieveld et al., 2016</xref>).</p><p>Whole genome sequencing was performed on tumor DNA as described previously (<xref ref-type="bibr" rid="bib44">NTHL1 study group et al., 2020</xref>) using the SureSelectXT Human All Exon V6 enrichment kit (Agilent Technologies, CA, USA) on a NextSeq500 sequencing platform (Illumina, CA, USA). Trimmed NextSeq 500 sequencing reads were aligned to hg19 by using BWA-MEM, and duplicates were flagged by using Picard Tools, version 1.90. Variants were called with Mutect2 (GATK version 4.1.0.0), with matched germline samples; variant filtering was performed as described (<xref ref-type="bibr" rid="bib44">NTHL1 study group et al., 2020</xref>). All variants were annotated using an in-house annotation pipeline and driver genes were selected based in the COSMIC cancer gene census.</p></sec><sec id="s4-3"><title>Exome variant interpretation</title><p>For the gene panel analysis, a bioinformatic in silico filter was applied to select for variants affecting the known cancer predisposition genes. This gene panel consisted of 114 established (OMIM) cancer predisposition genes in 2013, expanding to 232 genes in 2019. [<ext-link ext-link-type="uri" xlink:href="https://www.radboudumc.nl/getmedia/59c91c86-e6e0-433b-995a-4e91b8277572/HEREDITARY-CANCER-PANEL_DG217.aspx">https://www.radboudumc.nl/getmedia/59c91c86-e6e0-433b-995a-4e91b8277572/HEREDITARY-CANCER-PANEL_DG217.aspx</ext-link>]. All subsequent versions of this panel included the <italic>TINF2</italic> gene, because of its role in cancer predisposition in dyskeratosis congenita. Variants were filtered for coding, non-synonymous variants with population frequencies below 1% in our in-house database and evaluated regarding their possible pathogenicity. The latter was performed using population frequencies, nucleotide conservation scores (PhyloP), and in silico pathogenicity predictions (SIFT, Polyphen2, Mutation Taster).</p></sec><sec id="s4-4"><title>Transcript analysis</title><p>For transcript analysis in c.604G &gt; C mutant and control cells, RNA isolation (RNeasy Mini kit, Qiagen) and cDNA synthesis (Superscript IV Reverse Transcriptase, ThermoFisher) was performed according to standard protocols. <italic>TINF2</italic> transcripts were amplified, separated according to size, cloned into pCR-Topo and analyzed by Sanger Sequencing. Primers used:</p><list list-type="simple"><list-item><p>TINF2_transcriptfw (TINF2-exon2) 5’- <named-content content-type="sequence">TCCTGAAAGCCCTGAATCAC</named-content>-3’</p></list-item><list-item><p>TINF2_transcriptrv (TINF2-exon6) 5’-<named-content content-type="sequence">GGGTCTGGCATGGACTCTTA</named-content>-3’.</p></list-item></list></sec><sec id="s4-5"><title>Cell culture</title><p>293T cells (ATCC; not further authenticated) were grown in DMEM supplemented with 10% bovine calf serum (Hyclone), 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 0.1 mM nonessential amino acids. hTERT-RPE1 p53-/- Rb-/-cells (<xref ref-type="bibr" rid="bib64">Yang et al., 2017</xref>) were generated using RPE1 cells from the ATCC (not further authenticated) and cultured in DMEM/F12 (Gibco) supplemented with 10% fetal bovine serum (GIBCO), 100 U/ml penicillin (Sigma) and 0.1 mg/ml streptomycin (Sigma). Stem cell culture was performed as described previously (<xref ref-type="bibr" rid="bib8">Chiba et al., 2015</xref>) using WIBR#3 hESCs (NIH stem cell registry number: 0079; not further authenticated <xref ref-type="bibr" rid="bib35">Lengner et al., 2010</xref>). All cell lines were free of mycoplasma.</p></sec><sec id="s4-6"><title>Expression vectors</title><p>Vectors expressing N-terminally Flag-(HA)<sub>2</sub> tagged TIN2 and N-terminally Myc-tagged TRF1, TRF2, and TPP1 were as previously described (<xref ref-type="bibr" rid="bib53">Smogorzewska and de Lange, 2002</xref>; <xref ref-type="bibr" rid="bib16">Frescas and de Lange, 2014</xref>). Flag-(HA)<sub>2</sub>-TIN2 S186fs was cloned by site-directed mutagenesis (QuikChange II XL, Agilent Technologies). For the cloning of Flag-(HA)<sub>2</sub>-TIN2 L170fs and Flag-(HA)2-TIN2 E202fs, mutant transcripts were amplified from the cDNA recovered from c.604G &gt; C mutant cells (604G &gt; C homozyg) and the wild-type fragment in pLPC-Flag-(HA)<sub>2</sub>-Tin2 was replaced with the respective mutant <italic>BamH</italic>I/<italic>Blp</italic>I fragments.</p></sec><sec id="s4-7"><title>Co-immunoprecipitation and immunoblotting</title><p>For co-immunoprecipitation assays, Flag-(HA)<sub>2</sub> tagged TIN2 proteins were co-expressed with Myc-tagged TRF1, TRF2 or TPP1 in 293T cells. Cells were collected 36–48 hr after calcium phosphate transfection as previously described (<xref ref-type="bibr" rid="bib57">Takai et al., 2016</xref>). Lysates were diluted to lower the NaCl concentration to 200 mM for TPP1 and TRF1 and to 100 mM for TRF2 immunoprecipitations. HA-tagged TIN2 was precipitated using αHA agarose beads for 2 hr at 4°C, beads were washed with lysis buffer and PBS, proteins were eluted with Laemmli loading buffer and analyzed by immunoblotting using aHA antibody (HA.11, Covance) for TIN2 and Myc antibody (9B11, Cell signaling) for co-immunoprecipitated TRF1, TRF2, and TPP1. For TIN2 immunoblots, whole-cell lysates were prepared by lysis of cells in buffer C (20 mM Hepes-KOH pH 7.9, 0.42 M KCl, 25% glycerol, 0.1 mM EDTA, 5 mM MgCl<sub>2</sub>, 0.2% NP-40, complete protease inhibitor cocktail), quantified by Biuret protein assay and immunoblotted using antibodies for human TIN2 (#864) and γtubulin (GTU88, Sigma).</p></sec><sec id="s4-8"><title>Telomeric ChIP</title><p>Telomeric ChIP was performed as previously described (<xref ref-type="bibr" rid="bib37">Loayza and De Lange, 2003</xref>). Telomeric DNA associated with shelterin proteins was immunoprecipitated with the following crude sera or purified antibodies: crude rabbit TRF1 (#371), crude rabbit TIN2 (#865), crude rabbit TPP1 (#1151), POT1 (Abcam, ab123784), anti-HA (Abcam, ab9110) and protein G magnetic beads (Cell signaling). For ChIP of exogenously introduced TIN2 alleles, 293T cells were transfected by calcium phosphate transfection, and crosslinked and harvested 36–48 hr after transfection.</p></sec><sec id="s4-9"><title>CRISPR/Cas9-mediated targeting of <italic>TINF2</italic> in RPE-1 cells</title><p>Clonal cell lines with targeted <italic>TINF2</italic> alleles were generated using pU6-(BbsI)-Cbh-Cas9-T2a-mCherry (<xref ref-type="bibr" rid="bib9">Chu et al., 2015</xref>) that allows co-expression of sgRNA and Cas9 linked to mCherry via the T2A peptide. For the knock-in of <italic>TINF2</italic> mutations, the Cas9-sgRNA expression vector (TINF2exon5, sgRNA-1 or sgRNA-2) was delivered together with a 1:1 mix of the appropriate donor oligonucleotides (ssODN) by electroporation (Lonza). mCherry-positive cells were selected by single-cell sorting. Clones were screened by restriction enzyme digestion of PCR products and editing was verified by Sanger sequencing of Topo-cloned PCR products. For the generation of TINF2+/- cells, Cas9-sgRNA (TINF2exon1, sgRNA-3) was introduced by electroporation, mCherry-positive targeted cells were selected by single cell sorting. Clones were screened by Sanger sequencing of PCR products for introduction of mono-allelic indels creating frame-shift mutations in exon 1.</p><p>sgRNA oligonucleotides were purchased from ThermoFisher and cloned into BbsI-digested expression vector. The sequences are: sgRNA-1 5’-<named-content content-type="sequence">TTGTCTCCAGGCAAGAGAAG</named-content>-(PAM)−3’; sgRNA-2 5’-<named-content content-type="sequence">GACAATATGGTGTGGACATG</named-content>-(PAM)−3’; sgRNA-3 5’-<named-content content-type="sequence">ACGCCTTTGTATGGGCCTAA</named-content>-(PAM)−3’ ssODN were purchased from IDT and had the following sequences: c.557del-mut 5’-<named-content content-type="sequence">GCTTCAGGATGTGCTGAGTTGGATGCAGCCTGGAGTCTCTATCACTTCTTTCTTGCCTGGAGACAATATGGTGTAGACATGGGGTGGCTGCTTCCAGGTACTAGGAATTTGGAGGTGTAGTGTTTAGC</named-content>-3’; c.557del-control 5’-<named-content content-type="sequence">GCTTCAGGATGTGCTGAGTTGGATGCAGCCTGGAGTCTCTATCACTTCTTCTCTTGCCTGGAGACAATATGGTGTTGACATGGGGTGGCTGCTTCCAGGTACTAGGAATTTGGAGGTGTAGTGTTTAGC</named-content>-3’; c.604G &gt; C mut 5’-<named-content content-type="sequence">CAGCTTCAGGATGTGCTGAGTTGGATGCAGCCTGGAGTCTCTATCACCTCTTCTCTTGCCTGGAGACAATATGGTGTAGACATGGGATGGCTGCTTCCACGTACTAGGAATTTGGAGGTGTAGTGTTTAGCCTGAGACCTTTTGAGGCAGTCCACTGGAATAGTT</named-content>-3’.</p><p>c.604G &gt; C control 5’-<named-content content-type="sequence">CAGCTTCAGGATGTGCTGAGTTGGATGCAGCCTGGAGTCTCTATCACCTCTTCTCTTGCCTGGAGACAATATGGTGTTGACATGGGATGGCTGCTTCCAGGTACTAGGAATTTGGAGGTGTAGTGTTTAGCCTGAGACCTTTTGAGGCAGTCCACTGGAATAGTT</named-content>-3’.</p><p>For screening, the following primers were used: PCRscreen_exon5fw 5’-<named-content content-type="sequence">GGCCACTAACCCACTTTTG</named-content>-3’; PCRscreen_exon5rv 5’-<named-content content-type="sequence">CCTAGAGGGGCCAGATTGA</named-content>-3’; PCRscreen_exon1fw 5’-<named-content content-type="sequence">TTCCGCGAGTACTGGAGTTT</named-content>-3’; PCRscreen_exon1rv 5’-<named-content content-type="sequence">TCCCCTTCCAGGTCCTACTT</named-content>-3’.</p></sec><sec id="s4-10"><title>CRISPR/Cas9-mediated targeting of <italic>TINF2</italic> in hESCs</title><p>Stem cell culture and editing experiments were performed as described previously (<xref ref-type="bibr" rid="bib8">Chiba et al., 2015</xref>). To delete exons 4–7 of <italic>TINF2</italic> in WIBR#3 hESCs (NIH stem cell registry number: 0079; <xref ref-type="bibr" rid="bib35">Lengner et al., 2010</xref>), cells were co-electroporated with 15 ug of two PX330 Cas9 plasmids (<xref ref-type="bibr" rid="bib10">Cong et al., 2013</xref>), containing guide sequences 5′-<named-content content-type="sequence">TGTTCAAGTTCCTACAGCAG</named-content>-3′ and 5′-<named-content content-type="sequence">CCTGACTCAGACTACCTACC</named-content>-3′, respectively, and 7.5 µg of a GFP plasmid. Targeting was confirmed by PCR on genomic DNA using fw primer 5′-<named-content content-type="sequence">GGCCACTAACCCACTTTTGA</named-content>-3′ and rev primer 5′-<named-content content-type="sequence">TGGCCATTTTCTTCCTCATC</named-content>-3′ (Phusion, annealing temperature 63.4C, 1:15 min extension). Expected product sizes are 1275 bp for wild-type band and 218 bp for the exons 4–7 deletion.</p></sec><sec id="s4-11"><title>IF-FISH</title><p>For immunofluorescence in combination with telomeric FISH (IF-FISH), cells grown on coverslips to sub-confluence and were fixed in MeOH for 10 min at −20°C. IF-FISH was carried out as previously described (<xref ref-type="bibr" rid="bib55">Takai et al., 2003</xref>). The following affinity purified antibodies were used for IF: rabbit TRF2 (#647), rabbit TRF1 (#371), rabbit TIN2 2 (#864), rabbit 53BP1 (Abcam ab175933). Telomeric DNA was detected with FITC-OO-(CCCTAA)<sub>3</sub> PNA probe. Images were captured on a DeltaVision microscope (Applied Precision) equipped with a cooled charge-coupled device camera (DV Elite CMOS Camera), a PlanApo 60 × 1.42 NA objective (Olympus America), and SoftWoRx software.</p></sec><sec id="s4-12"><title>FISH and CO-FISH on metaphase chromosomes</title><p>Telomeric FISH and CO-FISH were conducted as previously described (<xref ref-type="bibr" rid="bib59">van Steensel et al., 1998</xref>; <xref ref-type="bibr" rid="bib5">Celli et al., 2006</xref>) using Alexa Fluor 647-OO-(TTAGGG)3, Cy3-OO-(TTAGGG)three or FITC-OO-(CCCTAA)three and a centromere probe (PNA Bio). Images were captured using a DeltaVision microscope (Applied Precision) equipped with a cooled charge-coupled device camera (DV Elite CMOS Camera) and a PlanApo 60 × 1.42 NA objective (Olympus America), and controlled by and SoftWoRx software.</p></sec><sec id="s4-13"><title>Flow-FISH</title><p>Flow-FISH analysis was performed by RepeatDX (Aachen, Germany) on DNA from patient peripheral blood lymphocytes according to standard protocols (<xref ref-type="bibr" rid="bib1">Alter et al., 2007</xref>).</p></sec><sec id="s4-14"><title>Telomere length analysis</title><p>For analysis of telomere length, cells were grown for 70 PDs and samples were harvested periodically by trypsinization, washed with 1x PBS, pelleted and frozen until further analysis. Genomic DNA was prepared as previously described (<xref ref-type="bibr" rid="bib11">de Lange et al., 1990</xref>). DNA for telomere length analysis was digested with <italic>Mbo</italic>I and <italic>Alu</italic>I, quantified using Hoechst 33259 fluorometry and 0.5–1 µg was run on 0.7% agarose gels in 0.5x TBE. The DNA was depurinated, denatured, and neutralized and transferred onto membrane as previously described (<xref ref-type="bibr" rid="bib11">de Lange et al., 1990</xref>). Blots were probed for telomeres using the Sty11 probe (<xref ref-type="bibr" rid="bib12">de Lange, 1992</xref>). Alternatively, telomere length was evaluated based on the hybridization of a probe to the 3′ overhang in native gels. For this, gels were dried and probed with an end-labeled (CCCTAA)<sub>4</sub> as previously described (<xref ref-type="bibr" rid="bib31">Karlseder et al., 2002</xref>). Gels and membranes were exposed to Phophorimager screens and quantified with Fiji.</p></sec><sec id="s4-15"><title>TRAP assay</title><p>TRAP assay was performed according to manufacturer’s descriptions (TRAPeze Telomerase Detection Kit, EMD Millipore). Reaction products were run on a native polyacrylamide gel and stained with ethidium bromide.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank the members of the de Lange lab for helpful discussion. John Zinder is thanked for generating the structural representation of the TIN2 truncations. Research reported in this publication was supported by grants from the NCI (R35CA210036), the Breast Cancer Research Foundation, and the Melanoma Research Alliance (MRA 577521) to T.d.L. T.d.L. is an American Cancer Society Rose Zarucki Trust Research Professor. D.H. is a Chan Zuckerburg Biohub Investigator, a Pew-Stewart Scholar for Cancer Research supported by the Pew Charitable Trusts and the Alexander and Margaret Stewart Trust. This research is supported by grants to D.H. from the Siebel Stem Cell Institute, the NIH (<ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/science/article/pii/S0959437X20300046?via%3Dihub#gs0025">R01-CA196884</ext-link>), the D.O.D. (W81XWH-19-1-0586), and a Research Scholar Grants from the American Cancer Society (<ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/science/article/pii/S0959437X20300046?via%3Dihub#gs0005">133396-RSG-19-029-01-DMC</ext-link>).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Member of the SAB of Calico Life Sciences LLC</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Supervision, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Supervision, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con4"><p>Data curation</p></fn><fn fn-type="con" id="con5"><p>Data curation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Data curation, Supervision, Funding acquisition, Investigation, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: This study was performed in accordance with the local Institutional Review Board and all participants (four probands and two affected relatives) provided written informed consent for publication of their data.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Uncropped images of immunoblots and telomere blots shown in the main figures.</title></caption><media mime-subtype="jpeg" mimetype="image" xlink:href="elife-61235-supp1-v1.jpg"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Uncropped images of immunoblots and telomere blots shown in the main figures.</title></caption><media mime-subtype="jpeg" mimetype="image" xlink:href="elife-61235-supp2-v1.jpg"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Uncropped images of immunoblots and telomere blots shown in the main figures.</title></caption><media mime-subtype="jpeg" mimetype="image" xlink:href="elife-61235-supp3-v1.jpg"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>p-Values and summary statistics for key data.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-61235-supp4-v1.pdf"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-61235-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided in the Supplementary files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alter</surname> <given-names>BP</given-names></name><name><surname>Baerlocher</surname> <given-names>GM</given-names></name><name><surname>Savage</surname> <given-names>SA</given-names></name><name><surname>Chanock</surname> <given-names>SJ</given-names></name><name><surname>Weksler</surname> <given-names>BB</given-names></name><name><surname>Willner</surname> <given-names>JP</given-names></name><name><surname>Peters</surname> <given-names>JA</given-names></name><name><surname>Giri</surname> <given-names>N</given-names></name><name><surname>Lansdorp</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita</article-title><source>Blood</source><volume>110</volume><fpage>1439</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-02-075598</pub-id><pub-id pub-id-type="pmid">17468339</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artandi</surname> <given-names>SE</given-names></name><name><surname>DePinho</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Mice without telomerase: what can they teach us about human Cancer?</article-title><source>Nature Medicine</source><volume>6</volume><fpage>852</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1038/78595</pub-id><pub-id pub-id-type="pmid">10932211</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodnar</surname> <given-names>AG</given-names></name><name><surname>Ouellette</surname> <given-names>M</given-names></name><name><surname>Frolkis</surname> <given-names>M</given-names></name><name><surname>Holt</surname> <given-names>SE</given-names></name><name><surname>Chiu</surname> <given-names>CP</given-names></name><name><surname>Morin</surname> <given-names>GB</given-names></name><name><surname>Harley</surname> <given-names>CB</given-names></name><name><surname>Shay</surname> <given-names>JW</given-names></name><name><surname>Lichtsteiner</surname> <given-names>S</given-names></name><name><surname>Wright</surname> <given-names>WE</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Extension of life-span by introduction of telomerase into normal human cells</article-title><source>Science</source><volume>279</volume><fpage>349</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1126/science.279.5349.349</pub-id><pub-id pub-id-type="pmid">9454332</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryan</surname> <given-names>TM</given-names></name><name><surname>Englezou</surname> <given-names>A</given-names></name><name><surname>Dunham</surname> <given-names>MA</given-names></name><name><surname>Reddel</surname> <given-names>RR</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Telomere Length Dynamics in Telomerase-Positive Immortal Human Cell Populations</article-title><source>Experimental Cell Research</source><volume>239</volume><fpage>370</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1006/excr.1997.3907</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname> <given-names>GB</given-names></name><name><surname>Denchi</surname> <given-names>EL</given-names></name><name><surname>de Lange</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Ku70 stimulates fusion of dysfunctional telomeres yet protects chromosome ends from homologous recombination</article-title><source>Nature Cell Biology</source><volume>8</volume><fpage>885</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1038/ncb1444</pub-id><pub-id pub-id-type="pmid">16845382</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>LY</given-names></name><name><surname>Redon</surname> <given-names>S</given-names></name><name><surname>Lingner</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The human CST complex is a terminator of telomerase activity</article-title><source>Nature</source><volume>488</volume><fpage>540</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1038/nature11269</pub-id><pub-id pub-id-type="pmid">22763445</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>C</given-names></name><name><surname>Gu</surname> <given-names>P</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Niu</surname> <given-names>S</given-names></name><name><surname>Sun</surname> <given-names>H</given-names></name><name><surname>Wu</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>N</given-names></name><name><surname>Peng</surname> <given-names>J</given-names></name><name><surname>Shi</surname> <given-names>S</given-names></name><name><surname>Fan</surname> <given-names>C</given-names></name><name><surname>Huang</surname> <given-names>M</given-names></name><name><surname>Wong</surname> <given-names>CC</given-names></name><name><surname>Gong</surname> <given-names>Q</given-names></name><name><surname>Kumar-Sinha</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>R</given-names></name><name><surname>Pusztai</surname> <given-names>L</given-names></name><name><surname>Rai</surname> <given-names>R</given-names></name><name><surname>Chang</surname> <given-names>S</given-names></name><name><surname>Lei</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structural insights into POT1-TPP1 interaction and POT1 C-terminal mutations in human Cancer</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14929</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14929</pub-id><pub-id pub-id-type="pmid">28393832</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiba</surname> <given-names>K</given-names></name><name><surname>Johnson</surname> <given-names>JZ</given-names></name><name><surname>Vogan</surname> <given-names>JM</given-names></name><name><surname>Wagner</surname> <given-names>T</given-names></name><name><surname>Boyle</surname> <given-names>JM</given-names></name><name><surname>Hockemeyer</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cancer-associated TERT promoter mutations abrogate telomerase silencing</article-title><source>eLife</source><volume>4</volume><elocation-id>e07918</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.07918</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname> <given-names>VT</given-names></name><name><surname>Weber</surname> <given-names>T</given-names></name><name><surname>Wefers</surname> <given-names>B</given-names></name><name><surname>Wurst</surname> <given-names>W</given-names></name><name><surname>Sander</surname> <given-names>S</given-names></name><name><surname>Rajewsky</surname> <given-names>K</given-names></name><name><surname>Kühn</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells</article-title><source>Nature Biotechnology</source><volume>33</volume><fpage>543</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1038/nbt.3198</pub-id><pub-id pub-id-type="pmid">25803306</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname> <given-names>L</given-names></name><name><surname>Ran</surname> <given-names>FA</given-names></name><name><surname>Cox</surname> <given-names>D</given-names></name><name><surname>Lin</surname> <given-names>S</given-names></name><name><surname>Barretto</surname> <given-names>R</given-names></name><name><surname>Habib</surname> <given-names>N</given-names></name><name><surname>Hsu</surname> <given-names>PD</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Jiang</surname> <given-names>W</given-names></name><name><surname>Marraffini</surname> <given-names>LA</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Multiplex genome engineering using CRISPR/Cas systems</article-title><source>Science</source><volume>339</volume><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1126/science.1231143</pub-id><pub-id pub-id-type="pmid">23287718</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lange</surname> <given-names>T</given-names></name><name><surname>Shiue</surname> <given-names>L</given-names></name><name><surname>Myers</surname> <given-names>RM</given-names></name><name><surname>Cox</surname> <given-names>DR</given-names></name><name><surname>Naylor</surname> <given-names>SL</given-names></name><name><surname>Killery</surname> <given-names>AM</given-names></name><name><surname>Varmus</surname> <given-names>HE</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Structure and variability of human chromosome ends</article-title><source>Molecular and Cellular Biology</source><volume>10</volume><fpage>518</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1128/MCB.10.2.518</pub-id><pub-id pub-id-type="pmid">2300052</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lange</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Human telomeres are attached to the nuclear matrix</article-title><source>The EMBO Journal</source><volume>11</volume><fpage>717</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1992.tb05104.x</pub-id><pub-id pub-id-type="pmid">1537344</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lange</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Shelterin-Mediated telomere protection</article-title><source>Annual Review of Genetics</source><volume>52</volume><fpage>223</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1146/annurev-genet-032918-021921</pub-id><pub-id pub-id-type="pmid">30208292</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denchi</surname> <given-names>EL</given-names></name><name><surname>de Lange</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1</article-title><source>Nature</source><volume>448</volume><fpage>1068</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1038/nature06065</pub-id><pub-id pub-id-type="pmid">17687332</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname> <given-names>X</given-names></name><name><surname>Hsu</surname> <given-names>S-J</given-names></name><name><surname>Kasbek</surname> <given-names>C</given-names></name><name><surname>Chaiken</surname> <given-names>M</given-names></name><name><surname>Price</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CTC1-mediated C-strand fill-in is an essential step in telomere length maintenance</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>4281</fpage><lpage>4293</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx125</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frescas</surname> <given-names>D</given-names></name><name><surname>de Lange</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TRF2-tethered TIN2 can mediate telomere protection by TPP1/POT1</article-title><source>Molecular and Cellular Biology</source><volume>34</volume><fpage>1349</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1128/MCB.01052-13</pub-id><pub-id pub-id-type="pmid">24469404</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname> <given-names>NMV</given-names></name><name><surname>Ryder</surname> <given-names>OA</given-names></name><name><surname>Houck</surname> <given-names>ML</given-names></name><name><surname>Charter</surname> <given-names>SJ</given-names></name><name><surname>Walker</surname> <given-names>W</given-names></name><name><surname>Forsyth</surname> <given-names>NR</given-names></name><name><surname>Austad</surname> <given-names>SN</given-names></name><name><surname>Venditti</surname> <given-names>C</given-names></name><name><surname>Pagel</surname> <given-names>M</given-names></name><name><surname>Shay</surname> <given-names>JW</given-names></name><name><surname>Wright</surname> <given-names>WE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Comparative biology of mammalian telomeres: hypotheses on ancestral states and the roles of telomeres in longevity determination</article-title><source>Aging Cell</source><volume>10</volume><fpage>761</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1111/j.1474-9726.2011.00718.x</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname> <given-names>Y</given-names></name><name><surname>Stock</surname> <given-names>AJ</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The enigma of excessively long telomeres in Cancer: lessons learned from rare human POT1 variants</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>60</volume><fpage>48</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2020.02.002</pub-id><pub-id pub-id-type="pmid">32155570</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname> <given-names>P</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Bisht</surname> <given-names>KK</given-names></name><name><surname>Wu</surname> <given-names>L</given-names></name><name><surname>Kukova</surname> <given-names>L</given-names></name><name><surname>Smith</surname> <given-names>EM</given-names></name><name><surname>Xiao</surname> <given-names>Y</given-names></name><name><surname>Bailey</surname> <given-names>SM</given-names></name><name><surname>Lei</surname> <given-names>M</given-names></name><name><surname>Nandakumar</surname> <given-names>J</given-names></name><name><surname>Chang</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Pot1 OB-fold mutations unleash telomere instability to initiate tumorigenesis</article-title><source>Oncogene</source><volume>36</volume><fpage>1939</fpage><lpage>1951</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.405</pub-id><pub-id pub-id-type="pmid">27869160</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname> <given-names>WC</given-names></name><name><surname>Counter</surname> <given-names>CM</given-names></name><name><surname>Lundberg</surname> <given-names>AS</given-names></name><name><surname>Beijersbergen</surname> <given-names>RL</given-names></name><name><surname>Brooks</surname> <given-names>MW</given-names></name><name><surname>Weinberg</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Creation of human tumour cells with defined genetic elements</article-title><source>Nature</source><volume>400</volume><fpage>464</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1038/22780</pub-id><pub-id pub-id-type="pmid">10440377</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harley</surname> <given-names>CB</given-names></name><name><surname>Futcher</surname> <given-names>AB</given-names></name><name><surname>Greider</surname> <given-names>CW</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Telomeres shorten during ageing of human fibroblasts</article-title><source>Nature</source><volume>345</volume><fpage>458</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1038/345458a0</pub-id><pub-id pub-id-type="pmid">2342578</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harley</surname> <given-names>CB</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Blasco</surname> <given-names>M</given-names></name><name><surname>Vera</surname> <given-names>E</given-names></name><name><surname>Andrews</surname> <given-names>WH</given-names></name><name><surname>Briggs</surname> <given-names>LA</given-names></name><name><surname>Raffaele</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A natural product telomerase activator as part of a health maintenance program</article-title><source>Rejuvenation Research</source><volume>14</volume><fpage>45</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1089/rej.2010.1085</pub-id><pub-id pub-id-type="pmid">20822369</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hastie</surname> <given-names>ND</given-names></name><name><surname>Dempster</surname> <given-names>M</given-names></name><name><surname>Dunlop</surname> <given-names>MG</given-names></name><name><surname>Thompson</surname> <given-names>AM</given-names></name><name><surname>Green</surname> <given-names>DK</given-names></name><name><surname>Allshire</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Telomere reduction in human colorectal carcinoma and with ageing</article-title><source>Nature</source><volume>346</volume><fpage>866</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1038/346866a0</pub-id><pub-id pub-id-type="pmid">2392154</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Comiskey</surname> <given-names>DF</given-names></name><name><surname>Liyanarachchi</surname> <given-names>S</given-names></name><name><surname>Nieminen</surname> <given-names>TT</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>DeLap</surname> <given-names>KE</given-names></name><name><surname>Brock</surname> <given-names>P</given-names></name><name><surname>de la Chapelle</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A truncating germline mutation of <italic>TINF2</italic> in Individuals with Thyroid Cancer or Melanoma Results in Longer Telomeres</article-title><source>Thyroid</source><volume>30</volume><fpage>204</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1089/thy.2019.0156</pub-id><pub-id pub-id-type="pmid">31928178</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemann</surname> <given-names>MT</given-names></name><name><surname>Strong</surname> <given-names>MA</given-names></name><name><surname>Hao</surname> <given-names>LY</given-names></name><name><surname>Greider</surname> <given-names>CW</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability</article-title><source>Cell</source><volume>107</volume><fpage>67</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00504-9</pub-id><pub-id pub-id-type="pmid">11595186</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hockemeyer</surname> <given-names>D</given-names></name><name><surname>Collins</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Control of telomerase action at human telomeres</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>22</volume><fpage>848</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1038/nsmb.3083</pub-id><pub-id pub-id-type="pmid">26581518</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname> <given-names>S</given-names></name><name><surname>Figl</surname> <given-names>A</given-names></name><name><surname>Rachakonda</surname> <given-names>PS</given-names></name><name><surname>Fischer</surname> <given-names>C</given-names></name><name><surname>Sucker</surname> <given-names>A</given-names></name><name><surname>Gast</surname> <given-names>A</given-names></name><name><surname>Kadel</surname> <given-names>S</given-names></name><name><surname>Moll</surname> <given-names>I</given-names></name><name><surname>Nagore</surname> <given-names>E</given-names></name><name><surname>Hemminki</surname> <given-names>K</given-names></name><name><surname>Schadendorf</surname> <given-names>D</given-names></name><name><surname>Kumar</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TERT promoter mutations in familial and sporadic melanoma</article-title><source>Science</source><volume>339</volume><fpage>959</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1126/science.1230062</pub-id><pub-id pub-id-type="pmid">23348503</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>C</given-names></name><name><surname>Rai</surname> <given-names>R</given-names></name><name><surname>Huang</surname> <given-names>C</given-names></name><name><surname>Broton</surname> <given-names>C</given-names></name><name><surname>Long</surname> <given-names>J</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Xue</surname> <given-names>J</given-names></name><name><surname>Lei</surname> <given-names>M</given-names></name><name><surname>Chang</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structural and functional analyses of the mammalian TIN2-TPP1-TRF2 telomeric complex</article-title><source>Cell Research</source><volume>27</volume><fpage>1485</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1038/cr.2017.144</pub-id><pub-id pub-id-type="pmid">29160297</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>FW</given-names></name><name><surname>Hodis</surname> <given-names>E</given-names></name><name><surname>Xu</surname> <given-names>MJ</given-names></name><name><surname>Kryukov</surname> <given-names>GV</given-names></name><name><surname>Chin</surname> <given-names>L</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Highly recurrent TERT promoter mutations in human melanoma</article-title><source>Science</source><volume>339</volume><fpage>957</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1126/science.1229259</pub-id><pub-id pub-id-type="pmid">23348506</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huffman</surname> <given-names>KE</given-names></name><name><surname>Levene</surname> <given-names>SD</given-names></name><name><surname>Tesmer</surname> <given-names>VM</given-names></name><name><surname>Shay</surname> <given-names>JW</given-names></name><name><surname>Wright</surname> <given-names>WE</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Telomere shortening is proportional to the size of the G-rich telomeric 3'-overhang</article-title><source>Journal of Biological Chemistry</source><volume>275</volume><fpage>19719</fpage><lpage>19722</lpage><pub-id pub-id-type="doi">10.1074/jbc.M002843200</pub-id><pub-id pub-id-type="pmid">10787419</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlseder</surname> <given-names>J</given-names></name><name><surname>Smogorzewska</surname> <given-names>A</given-names></name><name><surname>de Lange</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Senescence induced by altered telomere state, not telomere loss</article-title><source>Science</source><volume>295</volume><fpage>2446</fpage><lpage>2449</lpage><pub-id pub-id-type="doi">10.1126/science.1069523</pub-id><pub-id pub-id-type="pmid">11923537</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>S-ho</given-names></name><name><surname>Kaminker</surname> <given-names>P</given-names></name><name><surname>Campisi</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>TIN2, a new regulator of telomere length in human cells</article-title><source>Nature Genetics</source><volume>23</volume><fpage>405</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1038/70508</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kipling</surname> <given-names>D</given-names></name><name><surname>Cooke</surname> <given-names>HJ</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Hypervariable ultra-long telomeres in mice</article-title><source>Nature</source><volume>347</volume><fpage>400</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1038/347400a0</pub-id><pub-id pub-id-type="pmid">2170845</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lelieveld</surname> <given-names>SH</given-names></name><name><surname>Reijnders</surname> <given-names>MRF</given-names></name><name><surname>Pfundt</surname> <given-names>R</given-names></name><name><surname>Yntema</surname> <given-names>HG</given-names></name><name><surname>Kamsteeg</surname> <given-names>E-J</given-names></name><name><surname>de Vries</surname> <given-names>P</given-names></name><name><surname>de Vries</surname> <given-names>BBA</given-names></name><name><surname>Willemsen</surname> <given-names>MH</given-names></name><name><surname>Kleefstra</surname> <given-names>T</given-names></name><name><surname>Löhner</surname> <given-names>K</given-names></name><name><surname>Vreeburg</surname> <given-names>M</given-names></name><name><surname>Stevens</surname> <given-names>SJC</given-names></name><name><surname>van der Burgt</surname> <given-names>I</given-names></name><name><surname>Bongers</surname> <given-names>EMHF</given-names></name><name><surname>Stegmann</surname> <given-names>APA</given-names></name><name><surname>Rump</surname> <given-names>P</given-names></name><name><surname>Rinne</surname> <given-names>T</given-names></name><name><surname>Nelen</surname> <given-names>MR</given-names></name><name><surname>Veltman</surname> <given-names>JA</given-names></name><name><surname>Vissers</surname> <given-names>LELM</given-names></name><name><surname>Brunner</surname> <given-names>HG</given-names></name><name><surname>Gilissen</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability</article-title><source>Nature Neuroscience</source><volume>19</volume><fpage>1194</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1038/nn.4352</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lengner</surname> <given-names>CJ</given-names></name><name><surname>Gimelbrant</surname> <given-names>AA</given-names></name><name><surname>Erwin</surname> <given-names>JA</given-names></name><name><surname>Cheng</surname> <given-names>AW</given-names></name><name><surname>Guenther</surname> <given-names>MG</given-names></name><name><surname>Welstead</surname> <given-names>GG</given-names></name><name><surname>Alagappan</surname> <given-names>R</given-names></name><name><surname>Frampton</surname> <given-names>GM</given-names></name><name><surname>Xu</surname> <given-names>P</given-names></name><name><surname>Muffat</surname> <given-names>J</given-names></name><name><surname>Santagata</surname> <given-names>S</given-names></name><name><surname>Powers</surname> <given-names>D</given-names></name><name><surname>Barrett</surname> <given-names>CB</given-names></name><name><surname>Young</surname> <given-names>RA</given-names></name><name><surname>Lee</surname> <given-names>JT</given-names></name><name><surname>Jaenisch</surname> <given-names>R</given-names></name><name><surname>Mitalipova</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations</article-title><source>Cell</source><volume>141</volume><fpage>872</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.04.010</pub-id><pub-id pub-id-type="pmid">20471072</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Durbin</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Fast and accurate long-read alignment with Burrows-Wheeler transform</article-title><source>Bioinformatics</source><volume>26</volume><fpage>589</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp698</pub-id><pub-id pub-id-type="pmid">20080505</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loayza</surname> <given-names>D</given-names></name><name><surname>De Lange</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>POT1 as a terminal transducer of TRF1 telomere length control</article-title><source>Nature</source><volume>423</volume><fpage>1013</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1038/nature01688</pub-id><pub-id pub-id-type="pmid">12768206</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorbeer</surname> <given-names>FK</given-names></name><name><surname>Hockemeyer</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TERT promoter mutations and telomeres during tumorigenesis</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>60</volume><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2020.02.001</pub-id><pub-id pub-id-type="pmid">32163830</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maciejowski</surname> <given-names>J</given-names></name><name><surname>de Lange</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Telomeres in Cancer: tumour suppression and genome instability</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>18</volume><fpage>175</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/nrm.2016.171</pub-id><pub-id pub-id-type="pmid">28096526</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname> <given-names>A</given-names></name><name><surname>Hanna</surname> <given-names>M</given-names></name><name><surname>Banks</surname> <given-names>E</given-names></name><name><surname>Sivachenko</surname> <given-names>A</given-names></name><name><surname>Cibulskis</surname> <given-names>K</given-names></name><name><surname>Kernytsky</surname> <given-names>A</given-names></name><name><surname>Garimella</surname> <given-names>K</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><name><surname>Gabriel</surname> <given-names>S</given-names></name><name><surname>Daly</surname> <given-names>M</given-names></name><name><surname>DePristo</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title><source>Genome Research</source><volume>20</volume><fpage>1297</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1101/gr.107524.110</pub-id><pub-id pub-id-type="pmid">20644199</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNally</surname> <given-names>EJ</given-names></name><name><surname>Luncsford</surname> <given-names>PJ</given-names></name><name><surname>Armanios</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Long telomeres and Cancer risk: the price of cellular immortality</article-title><source>Journal of Clinical Investigation</source><volume>129</volume><fpage>3474</fpage><lpage>3481</lpage><pub-id pub-id-type="doi">10.1172/JCI120851</pub-id><pub-id pub-id-type="pmid">31380804</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandakumar</surname> <given-names>J</given-names></name><name><surname>Bell</surname> <given-names>CF</given-names></name><name><surname>Weidenfeld</surname> <given-names>I</given-names></name><name><surname>Zaug</surname> <given-names>AJ</given-names></name><name><surname>Leinwand</surname> <given-names>LA</given-names></name><name><surname>Cech</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity</article-title><source>Nature</source><volume>492</volume><fpage>285</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1038/nature11648</pub-id><pub-id pub-id-type="pmid">23103865</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>NCI DCEG Cancer Sequencing Working Group</collab><collab>NCI DCEG Cancer Genomics Research Laboratory</collab><collab>French Familial Melanoma Study Group</collab><name><surname>Shi</surname> <given-names>J</given-names></name><name><surname>Yang</surname> <given-names>XR</given-names></name><name><surname>Ballew</surname> <given-names>B</given-names></name><name><surname>Rotunno</surname> <given-names>M</given-names></name><name><surname>Calista</surname> <given-names>D</given-names></name><name><surname>Fargnoli</surname> <given-names>MC</given-names></name><name><surname>Ghiorzo</surname> <given-names>P</given-names></name><name><surname>Bressac-de Paillerets</surname> <given-names>B</given-names></name><name><surname>Nagore</surname> <given-names>E</given-names></name><name><surname>Avril</surname> <given-names>MF</given-names></name><name><surname>Caporaso</surname> <given-names>NE</given-names></name><name><surname>McMaster</surname> <given-names>ML</given-names></name><name><surname>Cullen</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Bruno</surname> <given-names>W</given-names></name><name><surname>Pastorino</surname> <given-names>L</given-names></name><name><surname>Queirolo</surname> <given-names>P</given-names></name><name><surname>Banuls-Roca</surname> <given-names>J</given-names></name><name><surname>Garcia-Casado</surname> <given-names>Z</given-names></name><name><surname>Vaysse</surname> <given-names>A</given-names></name><name><surname>Mohamdi</surname> <given-names>H</given-names></name><name><surname>Riazalhosseini</surname> <given-names>Y</given-names></name><name><surname>Foglio</surname> <given-names>M</given-names></name><name><surname>Jouenne</surname> <given-names>F</given-names></name><name><surname>Hua</surname> <given-names>X</given-names></name><name><surname>Hyland</surname> <given-names>PL</given-names></name><name><surname>Yin</surname> <given-names>J</given-names></name><name><surname>Vallabhaneni</surname> <given-names>H</given-names></name><name><surname>Chai</surname> <given-names>W</given-names></name><name><surname>Minghetti</surname> <given-names>P</given-names></name><name><surname>Pellegrini</surname> <given-names>C</given-names></name><name><surname>Ravichandran</surname> <given-names>S</given-names></name><name><surname>Eggermont</surname> <given-names>A</given-names></name><name><surname>Lathrop</surname> <given-names>M</given-names></name><name><surname>Peris</surname> <given-names>K</given-names></name><name><surname>Scarra</surname> <given-names>GB</given-names></name><name><surname>Landi</surname> <given-names>G</given-names></name><name><surname>Savage</surname> <given-names>SA</given-names></name><name><surname>Sampson</surname> <given-names>JN</given-names></name><name><surname>He</surname> <given-names>J</given-names></name><name><surname>Yeager</surname> <given-names>M</given-names></name><name><surname>Goldin</surname> <given-names>LR</given-names></name><name><surname>Demenais</surname> <given-names>F</given-names></name><name><surname>Chanock</surname> <given-names>SJ</given-names></name><name><surname>Tucker</surname> <given-names>MA</given-names></name><name><surname>Goldstein</surname> <given-names>AM</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Landi</surname> <given-names>MT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma</article-title><source>Nature Genetics</source><volume>46</volume><fpage>482</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1038/ng.2941</pub-id><pub-id pub-id-type="pmid">24686846</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>NTHL1 study group</collab><name><surname>Elsayed</surname> <given-names>FA</given-names></name><name><surname>Grolleman</surname> <given-names>JE</given-names></name><name><surname>Ragunathan</surname> <given-names>A</given-names></name><name><surname>Buchanan</surname> <given-names>DD</given-names></name><name><surname>van Wezel</surname> <given-names>T</given-names></name><name><surname>de Voer</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Monoallelic NTHL1 loss of function variants and risk of polyposis and colorectal Cancer</article-title><source>Gastroenterology</source><volume>5085</volume><elocation-id>35113</elocation-id><pub-id pub-id-type="doi">10.1053/j.gastro.2020.08.042</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinzaru</surname> <given-names>AM</given-names></name><name><surname>Hom</surname> <given-names>RA</given-names></name><name><surname>Beal</surname> <given-names>A</given-names></name><name><surname>Phillips</surname> <given-names>AF</given-names></name><name><surname>Ni</surname> <given-names>E</given-names></name><name><surname>Cardozo</surname> <given-names>T</given-names></name><name><surname>Nair</surname> <given-names>N</given-names></name><name><surname>Choi</surname> <given-names>J</given-names></name><name><surname>Wuttke</surname> <given-names>DS</given-names></name><name><surname>Sfeir</surname> <given-names>A</given-names></name><name><surname>Denchi</surname> <given-names>EL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Telomere replication stress induced by POT1 inactivation accelerates tumorigenesis</article-title><source>Cell Reports</source><volume>15</volume><fpage>2170</fpage><lpage>2184</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.05.008</pub-id><pub-id pub-id-type="pmid">27239034</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsay</surname> <given-names>AJ</given-names></name><name><surname>Quesada</surname> <given-names>V</given-names></name><name><surname>Foronda</surname> <given-names>M</given-names></name><name><surname>Conde</surname> <given-names>L</given-names></name><name><surname>Martínez-Trillos</surname> <given-names>A</given-names></name><name><surname>Villamor</surname> <given-names>N</given-names></name><name><surname>Rodríguez</surname> <given-names>D</given-names></name><name><surname>Kwarciak</surname> <given-names>A</given-names></name><name><surname>Garabaya</surname> <given-names>C</given-names></name><name><surname>Gallardo</surname> <given-names>M</given-names></name><name><surname>López-Guerra</surname> <given-names>M</given-names></name><name><surname>López-Guillermo</surname> <given-names>A</given-names></name><name><surname>Puente</surname> <given-names>XS</given-names></name><name><surname>Blasco</surname> <given-names>MA</given-names></name><name><surname>Campo</surname> <given-names>E</given-names></name><name><surname>López-Otín</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia</article-title><source>Nature Genetics</source><volume>45</volume><fpage>526</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1038/ng.2584</pub-id><pub-id pub-id-type="pmid">23502782</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robles-Espinoza</surname> <given-names>CD</given-names></name><name><surname>Harland</surname> <given-names>M</given-names></name><name><surname>Ramsay</surname> <given-names>AJ</given-names></name><name><surname>Aoude</surname> <given-names>LG</given-names></name><name><surname>Quesada</surname> <given-names>V</given-names></name><name><surname>Ding</surname> <given-names>Z</given-names></name><name><surname>Pooley</surname> <given-names>KA</given-names></name><name><surname>Pritchard</surname> <given-names>AL</given-names></name><name><surname>Tiffen</surname> <given-names>JC</given-names></name><name><surname>Petljak</surname> <given-names>M</given-names></name><name><surname>Palmer</surname> <given-names>JM</given-names></name><name><surname>Symmons</surname> <given-names>J</given-names></name><name><surname>Johansson</surname> <given-names>P</given-names></name><name><surname>Stark</surname> <given-names>MS</given-names></name><name><surname>Gartside</surname> <given-names>MG</given-names></name><name><surname>Snowden</surname> <given-names>H</given-names></name><name><surname>Montgomery</surname> <given-names>GW</given-names></name><name><surname>Martin</surname> <given-names>NG</given-names></name><name><surname>Liu</surname> <given-names>JZ</given-names></name><name><surname>Choi</surname> <given-names>J</given-names></name><name><surname>Makowski</surname> <given-names>M</given-names></name><name><surname>Brown</surname> <given-names>KM</given-names></name><name><surname>Dunning</surname> <given-names>AM</given-names></name><name><surname>Keane</surname> <given-names>TM</given-names></name><name><surname>López-Otín</surname> <given-names>C</given-names></name><name><surname>Gruis</surname> <given-names>NA</given-names></name><name><surname>Hayward</surname> <given-names>NK</given-names></name><name><surname>Bishop</surname> <given-names>DT</given-names></name><name><surname>Newton-Bishop</surname> <given-names>JA</given-names></name><name><surname>Adams</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>POT1 loss-of-function variants predispose to familial melanoma</article-title><source>Nature Genetics</source><volume>46</volume><fpage>478</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1038/ng.2947</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rode</surname> <given-names>L</given-names></name><name><surname>Nordestgaard</surname> <given-names>BG</given-names></name><name><surname>Bojesen</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Long telomeres and Cancer risk among 95 568 individuals from the general population</article-title><source>International Journal of Epidemiology</source><volume>45</volume><fpage>1634</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1093/ije/dyw179</pub-id><pub-id pub-id-type="pmid">27498151</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savage</surname> <given-names>SA</given-names></name><name><surname>Giri</surname> <given-names>N</given-names></name><name><surname>Baerlocher</surname> <given-names>GM</given-names></name><name><surname>Orr</surname> <given-names>N</given-names></name><name><surname>Lansdorp</surname> <given-names>PM</given-names></name><name><surname>Alter</surname> <given-names>BP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>TINF2, a Component of the Shelterin Telomere Protection Complex, Is Mutated in Dyskeratosis Congenita</article-title><source>The American Journal of Human Genetics</source><volume>82</volume><fpage>501</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2007.10.004</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savage</surname> <given-names>SA</given-names></name><name><surname>Bertuch</surname> <given-names>AA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The genetics and clinical manifestations of telomere biology disorders</article-title><source>Genetics in Medicine</source><volume>12</volume><fpage>753</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1097/GIM.0b013e3181f415b5</pub-id><pub-id pub-id-type="pmid">21189492</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shay</surname> <given-names>JW</given-names></name><name><surname>Bacchetti</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>A survey of telomerase activity in human Cancer</article-title><source>European Journal of Cancer</source><volume>33</volume><fpage>787</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(97)00062-2</pub-id><pub-id pub-id-type="pmid">9282118</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shay</surname> <given-names>JW</given-names></name><name><surname>Wright</surname> <given-names>WE</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Hayflick, his limit, and cellular ageing</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>1</volume><fpage>72</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1038/35036093</pub-id><pub-id pub-id-type="pmid">11413492</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smogorzewska</surname> <given-names>A</given-names></name><name><surname>de Lange</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Different telomere damage signaling pathways in human and mouse cells</article-title><source>The EMBO Journal</source><volume>21</volume><fpage>4338</fpage><lpage>4348</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdf433</pub-id><pub-id pub-id-type="pmid">12169636</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taboski</surname> <given-names>MA</given-names></name><name><surname>Sealey</surname> <given-names>DC</given-names></name><name><surname>Dorrens</surname> <given-names>J</given-names></name><name><surname>Tayade</surname> <given-names>C</given-names></name><name><surname>Betts</surname> <given-names>DH</given-names></name><name><surname>Harrington</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Long telomeres bypass the requirement for telomere maintenance in human tumorigenesis</article-title><source>Cell Reports</source><volume>1</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2011.12.004</pub-id><pub-id pub-id-type="pmid">22832159</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takai</surname> <given-names>H</given-names></name><name><surname>Smogorzewska</surname> <given-names>A</given-names></name><name><surname>de Lange</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>DNA damage foci at dysfunctional telomeres</article-title><source>Current Biology</source><volume>13</volume><fpage>1549</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.1016/S0960-9822(03)00542-6</pub-id><pub-id pub-id-type="pmid">12956959</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takai</surname> <given-names>KK</given-names></name><name><surname>Hooper</surname> <given-names>S</given-names></name><name><surname>Blackwood</surname> <given-names>S</given-names></name><name><surname>Gandhi</surname> <given-names>R</given-names></name><name><surname>de Lange</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title><italic>In</italic> vivo stoichiometry of shelterin components</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>1457</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.038026</pub-id><pub-id pub-id-type="pmid">19864690</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takai</surname> <given-names>H</given-names></name><name><surname>Jenkinson</surname> <given-names>E</given-names></name><name><surname>Kabir</surname> <given-names>S</given-names></name><name><surname>Babul-Hirji</surname> <given-names>R</given-names></name><name><surname>Najm-Tehrani</surname> <given-names>N</given-names></name><name><surname>Chitayat</surname> <given-names>DA</given-names></name><name><surname>Crow</surname> <given-names>YJ</given-names></name><name><surname>de Lange</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A POT1 mutation implicates defective telomere end fill-in and telomere truncations in coats plus</article-title><source>Genes &amp; Development</source><volume>30</volume><fpage>812</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1101/gad.276873.115</pub-id><pub-id pub-id-type="pmid">27013236</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Telomeres Mendelian Randomization Collaboration</collab><name><surname>Haycock</surname> <given-names>PC</given-names></name><name><surname>Burgess</surname> <given-names>S</given-names></name><name><surname>Nounu</surname> <given-names>A</given-names></name><name><surname>Zheng</surname> <given-names>J</given-names></name><name><surname>Okoli</surname> <given-names>GN</given-names></name><name><surname>Bowden</surname> <given-names>J</given-names></name><name><surname>Wade</surname> <given-names>KH</given-names></name><name><surname>Timpson</surname> <given-names>NJ</given-names></name><name><surname>Evans</surname> <given-names>DM</given-names></name><name><surname>Willeit</surname> <given-names>P</given-names></name><name><surname>Aviv</surname> <given-names>A</given-names></name><name><surname>Gaunt</surname> <given-names>TR</given-names></name><name><surname>Hemani</surname> <given-names>G</given-names></name><name><surname>Mangino</surname> <given-names>M</given-names></name><name><surname>Ellis</surname> <given-names>HP</given-names></name><name><surname>Kurian</surname> <given-names>KM</given-names></name><name><surname>Pooley</surname> <given-names>KA</given-names></name><name><surname>Eeles</surname> <given-names>RA</given-names></name><name><surname>Lee</surname> <given-names>JE</given-names></name><name><surname>Fang</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>WV</given-names></name><name><surname>Law</surname> <given-names>MH</given-names></name><name><surname>Bowdler</surname> <given-names>LM</given-names></name><name><surname>Iles</surname> <given-names>MM</given-names></name><name><surname>Yang</surname> <given-names>Q</given-names></name><name><surname>Worrall</surname> <given-names>BB</given-names></name><name><surname>Markus</surname> <given-names>HS</given-names></name><name><surname>Hung</surname> <given-names>RJ</given-names></name><name><surname>Amos</surname> <given-names>CI</given-names></name><name><surname>Spurdle</surname> <given-names>AB</given-names></name><name><surname>Thompson</surname> <given-names>DJ</given-names></name><name><surname>O'Mara</surname> <given-names>TA</given-names></name><name><surname>Wolpin</surname> <given-names>B</given-names></name><name><surname>Amundadottir</surname> <given-names>L</given-names></name><name><surname>Stolzenberg-Solomon</surname> <given-names>R</given-names></name><name><surname>Trichopoulou</surname> <given-names>A</given-names></name><name><surname>Onland-Moret</surname> <given-names>NC</given-names></name><name><surname>Lund</surname> <given-names>E</given-names></name><name><surname>Duell</surname> <given-names>EJ</given-names></name><name><surname>Canzian</surname> <given-names>F</given-names></name><name><surname>Severi</surname> <given-names>G</given-names></name><name><surname>Overvad</surname> <given-names>K</given-names></name><name><surname>Gunter</surname> <given-names>MJ</given-names></name><name><surname>Tumino</surname> <given-names>R</given-names></name><name><surname>Svenson</surname> <given-names>U</given-names></name><name><surname>van Rij</surname> <given-names>A</given-names></name><name><surname>Baas</surname> <given-names>AF</given-names></name><name><surname>Bown</surname> <given-names>MJ</given-names></name><name><surname>Samani</surname> <given-names>NJ</given-names></name><name><surname>van t'Hof</surname> <given-names>FNG</given-names></name><name><surname>Tromp</surname> <given-names>G</given-names></name><name><surname>Jones</surname> <given-names>GT</given-names></name><name><surname>Kuivaniemi</surname> <given-names>H</given-names></name><name><surname>Elmore</surname> <given-names>JR</given-names></name><name><surname>Johansson</surname> <given-names>M</given-names></name><name><surname>Mckay</surname> <given-names>J</given-names></name><name><surname>Scelo</surname> <given-names>G</given-names></name><name><surname>Carreras-Torres</surname> <given-names>R</given-names></name><name><surname>Gaborieau</surname> <given-names>V</given-names></name><name><surname>Brennan</surname> <given-names>P</given-names></name><name><surname>Bracci</surname> <given-names>PM</given-names></name><name><surname>Neale</surname> <given-names>RE</given-names></name><name><surname>Olson</surname> <given-names>SH</given-names></name><name><surname>Gallinger</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Petersen</surname> <given-names>GM</given-names></name><name><surname>Risch</surname> <given-names>HA</given-names></name><name><surname>Klein</surname> <given-names>AP</given-names></name><name><surname>Han</surname> <given-names>J</given-names></name><name><surname>Abnet</surname> <given-names>CC</given-names></name><name><surname>Freedman</surname> <given-names>ND</given-names></name><name><surname>Taylor</surname> <given-names>PR</given-names></name><name><surname>Maris</surname> <given-names>JM</given-names></name><name><surname>Aben</surname> <given-names>KK</given-names></name><name><surname>Kiemeney</surname> <given-names>LA</given-names></name><name><surname>Vermeulen</surname> <given-names>SH</given-names></name><name><surname>Wiencke</surname> <given-names>JK</given-names></name><name><surname>Walsh</surname> <given-names>KM</given-names></name><name><surname>Wrensch</surname> <given-names>M</given-names></name><name><surname>Rice</surname> <given-names>T</given-names></name><name><surname>Turnbull</surname> <given-names>C</given-names></name><name><surname>Litchfield</surname> <given-names>K</given-names></name><name><surname>Paternoster</surname> <given-names>L</given-names></name><name><surname>Standl</surname> <given-names>M</given-names></name><name><surname>Abecasis</surname> <given-names>GR</given-names></name><name><surname>SanGiovanni</surname> <given-names>JP</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Mijatovic</surname> <given-names>V</given-names></name><name><surname>Sapkota</surname> <given-names>Y</given-names></name><name><surname>Low</surname> <given-names>SK</given-names></name><name><surname>Zondervan</surname> <given-names>KT</given-names></name><name><surname>Montgomery</surname> <given-names>GW</given-names></name><name><surname>Nyholt</surname> <given-names>DR</given-names></name><name><surname>van Heel</surname> <given-names>DA</given-names></name><name><surname>Hunt</surname> <given-names>K</given-names></name><name><surname>Arking</surname> <given-names>DE</given-names></name><name><surname>Ashar</surname> <given-names>FN</given-names></name><name><surname>Sotoodehnia</surname> <given-names>N</given-names></name><name><surname>Woo</surname> <given-names>D</given-names></name><name><surname>Rosand</surname> <given-names>J</given-names></name><name><surname>Comeau</surname> <given-names>ME</given-names></name><name><surname>Brown</surname> <given-names>WM</given-names></name><name><surname>Silverman</surname> <given-names>EK</given-names></name><name><surname>Hokanson</surname> <given-names>JE</given-names></name><name><surname>Cho</surname> <given-names>MH</given-names></name><name><surname>Hui</surname> <given-names>J</given-names></name><name><surname>Ferreira</surname> <given-names>MA</given-names></name><name><surname>Thompson</surname> <given-names>PJ</given-names></name><name><surname>Morrison</surname> <given-names>AC</given-names></name><name><surname>Felix</surname> <given-names>JF</given-names></name><name><surname>Smith</surname> <given-names>NL</given-names></name><name><surname>Christiano</surname> <given-names>AM</given-names></name><name><surname>Petukhova</surname> <given-names>L</given-names></name><name><surname>Betz</surname> <given-names>RC</given-names></name><name><surname>Fan</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Zhu</surname> <given-names>C</given-names></name><name><surname>Langefeld</surname> <given-names>CD</given-names></name><name><surname>Thompson</surname> <given-names>SD</given-names></name><name><surname>Wang</surname> <given-names>F</given-names></name><name><surname>Lin</surname> <given-names>X</given-names></name><name><surname>Schwartz</surname> <given-names>DA</given-names></name><name><surname>Fingerlin</surname> <given-names>T</given-names></name><name><surname>Rotter</surname> <given-names>JI</given-names></name><name><surname>Cotch</surname> <given-names>MF</given-names></name><name><surname>Jensen</surname> <given-names>RA</given-names></name><name><surname>Munz</surname> <given-names>M</given-names></name><name><surname>Dommisch</surname> <given-names>H</given-names></name><name><surname>Schaefer</surname> <given-names>AS</given-names></name><name><surname>Han</surname> <given-names>F</given-names></name><name><surname>Ollila</surname> <given-names>HM</given-names></name><name><surname>Hillary</surname> <given-names>RP</given-names></name><name><surname>Albagha</surname> <given-names>O</given-names></name><name><surname>Ralston</surname> <given-names>SH</given-names></name><name><surname>Zeng</surname> <given-names>C</given-names></name><name><surname>Zheng</surname> <given-names>W</given-names></name><name><surname>Shu</surname> <given-names>XO</given-names></name><name><surname>Reis</surname> <given-names>A</given-names></name><name><surname>Uebe</surname> <given-names>S</given-names></name><name><surname>Hüffmeier</surname> <given-names>U</given-names></name><name><surname>Kawamura</surname> <given-names>Y</given-names></name><name><surname>Otowa</surname> <given-names>T</given-names></name><name><surname>Sasaki</surname> <given-names>T</given-names></name><name><surname>Hibberd</surname> <given-names>ML</given-names></name><name><surname>Davila</surname> <given-names>S</given-names></name><name><surname>Xie</surname> <given-names>G</given-names></name><name><surname>Siminovitch</surname> <given-names>K</given-names></name><name><surname>Bei</surname> <given-names>JX</given-names></name><name><surname>Zeng</surname> <given-names>YX</given-names></name><name><surname>Försti</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>B</given-names></name><name><surname>Landi</surname> <given-names>S</given-names></name><name><surname>Franke</surname> <given-names>A</given-names></name><name><surname>Fischer</surname> <given-names>A</given-names></name><name><surname>Ellinghaus</surname> <given-names>D</given-names></name><name><surname>Flores</surname> <given-names>C</given-names></name><name><surname>Noth</surname> <given-names>I</given-names></name><name><surname>Ma</surname> <given-names>SF</given-names></name><name><surname>Foo</surname> <given-names>JN</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>JW</given-names></name><name><surname>Cox</surname> <given-names>DG</given-names></name><name><surname>Delattre</surname> <given-names>O</given-names></name><name><surname>Mirabeau</surname> <given-names>O</given-names></name><name><surname>Skibola</surname> <given-names>CF</given-names></name><name><surname>Tang</surname> <given-names>CS</given-names></name><name><surname>Garcia-Barcelo</surname> <given-names>M</given-names></name><name><surname>Chang</surname> <given-names>KP</given-names></name><name><surname>Su</surname> <given-names>WH</given-names></name><name><surname>Chang</surname> <given-names>YS</given-names></name><name><surname>Martin</surname> <given-names>NG</given-names></name><name><surname>Gordon</surname> <given-names>S</given-names></name><name><surname>Wade</surname> <given-names>TD</given-names></name><name><surname>Lee</surname> <given-names>C</given-names></name><name><surname>Kubo</surname> <given-names>M</given-names></name><name><surname>Cha</surname> <given-names>PC</given-names></name><name><surname>Nakamura</surname> <given-names>Y</given-names></name><name><surname>Levy</surname> <given-names>D</given-names></name><name><surname>Kimura</surname> <given-names>M</given-names></name><name><surname>Hwang</surname> <given-names>SJ</given-names></name><name><surname>Hunt</surname> <given-names>S</given-names></name><name><surname>Spector</surname> <given-names>T</given-names></name><name><surname>Soranzo</surname> <given-names>N</given-names></name><name><surname>Manichaikul</surname> <given-names>AW</given-names></name><name><surname>Barr</surname> <given-names>RG</given-names></name><name><surname>Kahali</surname> <given-names>B</given-names></name><name><surname>Speliotes</surname> <given-names>E</given-names></name><name><surname>Yerges-Armstrong</surname> <given-names>LM</given-names></name><name><surname>Cheng</surname> <given-names>CY</given-names></name><name><surname>Jonas</surname> <given-names>JB</given-names></name><name><surname>Wong</surname> <given-names>TY</given-names></name><name><surname>Fogh</surname> <given-names>I</given-names></name><name><surname>Lin</surname> <given-names>K</given-names></name><name><surname>Powell</surname> <given-names>JF</given-names></name><name><surname>Rice</surname> <given-names>K</given-names></name><name><surname>Relton</surname> <given-names>CL</given-names></name><name><surname>Martin</surname> <given-names>RM</given-names></name><name><surname>Davey Smith</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Association between telomere length and risk of Cancer and Non-Neoplastic diseases: a mendelian randomization study</article-title><source>JAMA Oncology</source><volume>3</volume><fpage>636</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2016.5945</pub-id><pub-id pub-id-type="pmid">28241208</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Steensel</surname> <given-names>B</given-names></name><name><surname>Smogorzewska</surname> <given-names>A</given-names></name><name><surname>de Lange</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>TRF2 protects human telomeres from end-to-end fusions</article-title><source>Cell</source><volume>92</volume><fpage>401</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80932-0</pub-id><pub-id pub-id-type="pmid">9476899</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Steensel</surname> <given-names>B</given-names></name><name><surname>de Lange</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Control of telomere length by the human telomeric protein TRF1</article-title><source>Nature</source><volume>385</volume><fpage>740</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1038/385740a0</pub-id><pub-id pub-id-type="pmid">9034193</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walne</surname> <given-names>AJ</given-names></name><name><surname>Vulliamy</surname> <given-names>T</given-names></name><name><surname>Beswick</surname> <given-names>R</given-names></name><name><surname>Kirwan</surname> <given-names>M</given-names></name><name><surname>Dokal</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes</article-title><source>Blood</source><volume>112</volume><fpage>3594</fpage><lpage>3600</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-05-153445</pub-id><pub-id pub-id-type="pmid">18669893</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname> <given-names>M</given-names></name><name><surname>Qin</surname> <given-names>J</given-names></name><name><surname>Songyang</surname> <given-names>Z</given-names></name><name><surname>Liu</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>OB Fold-containing Protein 1 (OBFC1), a Human Homolog of Yeast Stn1, Associates with TPP1 and Is Implicated in Telomere Length Regulation</article-title><source>Journal of Biological Chemistry</source><volume>284</volume><fpage>26725</fpage><lpage>26731</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.021105</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname> <given-names>WE</given-names></name><name><surname>Piatyszek</surname> <given-names>MA</given-names></name><name><surname>Rainey</surname> <given-names>WE</given-names></name><name><surname>Byrd</surname> <given-names>W</given-names></name><name><surname>Shay</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Telomerase activity in human germline and embryonic tissues and cells</article-title><source>Developmental Genetics</source><volume>18</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1520-6408(1996)18:2&lt;173::AID-DVG10&gt;3.0.CO;2-3</pub-id><pub-id pub-id-type="pmid">8934879</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Maciejowski</surname> <given-names>J</given-names></name><name><surname>de Lange</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Nuclear envelope rupture is enhanced by loss of p53 or rb</article-title><source>Molecular Cancer Research</source><volume>15</volume><fpage>1579</fpage><lpage>1586</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-17-0084</pub-id><pub-id pub-id-type="pmid">28811362</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>JZ</given-names></name><name><surname>de Lange</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>TIN2 is a tankyrase 1 PARP modulator in the TRF1 telomere length control complex</article-title><source>Nature Genetics</source><volume>36</volume><fpage>618</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1038/ng1360</pub-id><pub-id pub-id-type="pmid">15133513</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname> <given-names>FL</given-names></name><name><surname>Batista</surname> <given-names>LF</given-names></name><name><surname>Freund</surname> <given-names>A</given-names></name><name><surname>Pech</surname> <given-names>MF</given-names></name><name><surname>Venteicher</surname> <given-names>AS</given-names></name><name><surname>Artandi</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>TPP1 OB-fold domain controls telomere maintenance by recruiting telomerase to chromosome ends</article-title><source>Cell</source><volume>150</volume><fpage>481</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.07.012</pub-id><pub-id pub-id-type="pmid">22863003</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname> <given-names>Y</given-names></name><name><surname>Sfeir</surname> <given-names>A</given-names></name><name><surname>Gryaznov</surname> <given-names>SM</given-names></name><name><surname>Shay</surname> <given-names>JW</given-names></name><name><surname>Wright</surname> <given-names>WE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Does a sentinel or a subset of short telomeres determine replicative senescence?</article-title><source>Molecular Biology of the Cell</source><volume>15</volume><fpage>3709</fpage><lpage>3718</lpage><pub-id pub-id-type="doi">10.1091/mbc.e04-03-0207</pub-id><pub-id pub-id-type="pmid">15181152</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.61235.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Wellinger</surname><given-names>Raymund J</given-names></name><role>Reviewing Editor</role><aff><institution>Fac Medecine/Université de Sherbrooke</institution><country>Canada</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Lingner</surname><given-names>Joachim</given-names> </name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The experiments presented in this manuscript directly probe and validate the previously assumed idea that a germline telomere over-elongation down the line permits more cell divisions to occur. These extra cell divisions will allow for more chances for other mutations to accumulate such that full-fledged cancer incidence increases and tumors arise quite early in life. Therefore, these results provide strong evidence that <italic>TINF2</italic> indeed is a haploinsufficient tumor suppressor gene that acts only through telomere length restriction. The ramifications of these findings go as far as strongly caution against the use of any manipulations aimed at elongating telomeres in people.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;<italic>TINF2</italic> is a haploinsufficient tumor suppressor that limits telomere length&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Richard White as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Joachim Lingner (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as <italic>eLife</italic> papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.</p><p>I am happy to write that reviewers commented very positive about it. They did indeed feel that an important question was addressed and that the results were clear and telling. They agree with you in that they thought that conceptually; this work is very important as is it supports the notion that overly long telomeres promote tumor formation presumably by delaying the onset of cellular senescence.</p><p>However, there were also some suggestions and questions relating to the data. We are aware that much of your data are derived from patient samples and perhaps not available for further experimentation and that will of course be taken in consideration for the final decision.</p><p>1) If cancer sequencing is available, one might ask whether the cancers in the affected people have anything else in common? Undoubtedly additional mutations are required for malignant transformation. If there are no unusual commonalities, this should be stated, since it is a bold discovery that simple telomere elongation leads to malignancy predisposition.</p><p>2) Perhaps another prediction would be that in patients with <italic>TINF2</italic>-mutations premalignant lesions containing senescent cells should be unusually large. Or did the patients even carry tumors without upregulating hTERT expression?</p><p>3) Effects on telomere elongation by homologous recombination or the telomere shortening rate are not excluded. Therefore, it appears reasonable to address this issue. In order to test the roles of telomerase, the telomere length kinetics could be assessed upon deletion of a telomerase subunit or the inhibition of telomerase with the BIBR or GRN inhibitors.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.61235.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>[…] There were also some suggestions and questions relating to the data. We are aware that much of your data are derived from patient samples and perhaps not available for further experimentation and that will of course be taken in consideration for the final decision.</p><p>1) If cancer sequencing is available, one might ask whether the cancers in the affected people have anything else in common? Undoubtedly additional mutations are required for malignant transformation. If there are no unusual commonalities, this should be stated, since it is a bold discovery that simple telomere elongation leads to malignancy predisposition.</p></disp-quote><p>We have now added exome sequencing data that indicates no special pattern of oncogenic mutations. The accompanying text is:</p><p>&quot;No loss of heterozygosity was detected in six tumors tested and second hits in <italic>TINF2</italic> were excluded in four of the six tumors analyzed by whole-exome sequencing (F3:III-1; Astrocytoma, F2:II-1; Melanoma and breast cancer, F1:II-4; colorectal cancer (CRC), see also Figure 1—figure supplement 2). […] The tumors did not reveal a shared somatic mutational spectrum (data not shown).&quot;</p><disp-quote content-type="editor-comment"><p>2) Perhaps another prediction would be that in patients with TINF2-mutations premalignant lesions containing senescent cells should be unusually large. Or did the patients even carry tumors without upregulating hTERT expression?</p></disp-quote><p>This is an interesting question but not one we can answer with the limited number of patient samples available. Hopefully, more insight into these issues will be obtained when more patients become available in the future.</p><disp-quote content-type="editor-comment"><p>3) Effects on telomere elongation by homologous recombination or the telomere shortening rate are not excluded. Therefore, it appears reasonable to address this issue. In order to test the roles of telomerase, the telomere length kinetics could be assessed upon deletion of a telomerase subunit or the inhibition of telomerase with the BIBR or GRN inhibitors.</p></disp-quote><p>To address the dependence of the telomere elongation phenotype on telomerase would take us a very long time. Because BIBR often only partially inhibits telomerase, we would have to do bulk CRISPR/Cas9 KO of hTERT or TERC in our clones (18 total). This will likely take months to optimize before we can initiate the telomere elongation experiments which themselves take several months. We note that TIN2 has been documented as a major regulator of telomerase-mediated telomere elongation by the Campisi lab (Kim et al., 1999) and others, making it likely that it acts through the telomerase pathway in our experiments.</p><p>However, we were able to address the alternative possibility that telomere elongation in our heterozygous cell lines is due to telomere recombination. We show that the level of T-SCEs (readout for telomere recombination) is not increased in the heterozygous mutant cell lines. Furthermore, the telomere blots do not show the heterogenous telomere length patterns typical of ALT lines. The text regarding these issues is as follows:</p><p>&quot;The observed telomere elongation is likely due to telomerase-mediated elongation since there was no evidence for increased telomere recombination in the cell lines (Figure 5—figure supplement 3) and the telomeres did not show the typical heterogeneous size of ALT telomeres (Figure 5). An effect of TIN2 on telomerase-mediated telomere elongation is consistent with prior data showing that a truncated TIN2 protein induced dramatic telomere elongation in cells expressing telomerase but had no effect in telomerase-negative cells (Kim et al., 1999).&quot;</p></body></sub-article></article>